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The inflammation and stress responses are intimately related adaptive responses to 
pathogens or other stressors upsetting our body’s homeostasis. However, when infections 
or other stressors persist-or are sufficiently traumatic-our normally adaptive responses 
become maladaptive compromising our immune system and mental wellbeing. Depression 
accounts for ~33% of debilitating mental illness worldwide. Recently, studies have 
outlined mechanisms by which stressors inducing proinflammatory cytokines or 
glucocorticoids precipitate symptoms of depression. Central to this hypothesis are the 
glucocorticoid- and cytokine-inducible enzymes tryptophan and indoleamine 2,3-
dioxygenases (DOs: Tdo2, Ido1 and Ido2). The DOs are rate-limiting for tryptophan 
metabolism by the Kynurenine Pathway. While accumulating evidence supports an 
interconnection between symptoms of depression and increased Kynurenine Pathway 
activity, the cellular specificity underpinning DO regulation by stress and inflammation 
remain poorly defined. Thus, (Chapter 1) after a review of the relevant literature, this 
thesis probes the regulation of DO expression (Chapter 2) by acute stress, and (Chapter 3) 
by peripheral inflammation and glucocorticoids, within the mouse brain, astrocytes, 
microglia, and peripheral tissues. We identify a unique role for astrocytes in the DO 
response to stress, and describe unique regulation patterns for astrocytes and microglia in 
the DO response to inflammation and glucocorticoids. Finally, using Cre-lox mediated cell-
specific knockdown of Ido1 in mice, we probe the contributions of myeloid- and neuron-
derived Ido1 to inflammation-induced anhedonia-like behavior reveling that myeloid-
derived Ido1 contributes to inflammation-induced anhedonia. Together, the data highlight 
glia- and tissue-specific DO regulation by stress and inflammation, and cell-specific 
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CHAPTER 1: Introduction 
1.1 Stress and stressors 
In 1936, the Austrian-Canadian physician Hans Selye began to convince the world of his 
understanding of stress [1]. Dr. Selye is the ‘father of stress’ and borrowed the term, in analogy, 
from physics and material science which define stress (force-per-unit-area) as proportional to 
strain (or a percent-change-in-length). Thus, physicists and engineers investigate stress in solid 
materials within the context of applied or inherent strains. Likewise, stress biologists investigate 
biological stress within the context of applied or inherent stressors. In Selye’s own words, “This 
distinction between stressor and stress was perhaps the first important step in the scientific 
analysis of that most common biologic phenomenon that we all know only too well”. Even so, 
often the term ‘stress’ is applied loosely and imprecisely outside of the stricter definitions 
applied within the discipline of stress biology [2]. This is a likely consequence of the explosive 
growth (Figure 1) of research into stress biology.  
 
Figure 1. PubMed indexed manuscripts containing "Stress Response" 
Stress results from homeostatic perturbations, or stressors, which activate the 
hypothalamic-pituitary-adrenal (HPA) axis and stimulate the immune system [3]. Indeed, the 
“stress response” is classically described by a fast sympathetic nervous system response 
mediated primarily by neurotransmitter action, followed by a relatively slow endocrine HPA 



























































stress response is normally adaptive and necessary for survival; it facilitates adaptation to 
external stressors like shifts in ambient temperature [1] and prepares us for fight or flight [3]. 
Stressful situations alter behavior, with even acute stressors resulting in changes in cognition 
[4], [5]. The stress response also involves precise regulation of neuronal plasticity [3], 
neurogenesis [6], and changes in the central and peripheral immune-physiology [7].  
1.2 Inflammation and Stress 
The stress response is associated with immunological changes both in the peripheral 
and central nervous systems [7]. In men for instance, the sensitivity of their peripheral immune 
cells to the anti-inflammatory action of glucocorticoids is increased following an acutely 
stressful situation [8]. Moreover, norepinephrine, the primary neurotransmitter of the 
sympathetic nervous system, can augment immune cell activity [9]. By contrast, stimulation of 
the vagus nerve, the primary efferent nerve of the parasympathetic nervous system, has anti-
inflammatory effects [10]. Thus, the stress response can modulate the immune system 
response by way of direct neuronal and indirect HPA axis (glucocorticoid) mediated pathways.  
The immune system and the stress response are intricately and bidirectional related. For 
instance, glucocorticoid activity is necessary to control the pro-inflammatory response 
following infection [11], and absence of glucocorticoids is associated with transient increases in 
pro-inflammatory cytokines [12]. By contrast, psychological stress [13], [14] or glucocorticoids 
[15]–[17] can actually be sensitizing so that a subsequent immune challenge is associated with 
an exacerbated immune response. Indeed, timing of glucocorticoid administration relative to an 
immune challenge can determine the nature of the cytokine response [17]. For example, 
glucocorticoid exposure 2 h before an immune challenge potentiates pro-inflammatory 
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cytokine expression in brain and liver, whereas glucocorticoid exposure 1 h after LPS suppresses 
the same LPS-induced responses [14], [18], [19].  
Acute stress results in increased brain expression of inflammatory mediators such as IL-
1β [20] TNFα [21], [22] and iNOS [23]. While both the HPA axis and autonomic nervous system 
activity contribute to the increases in peripheral and central pro-inflammatory mediators 
following stress [7], [24], the proinflammatory cytokines IL-1β[25], TNFα[26], and IL-6[27] 
administered systemically also activate the HPA axis. The mechanisms by which these 
inflammatory mediators might regulate the stress response (or vice versa) is fascinating but 
unfortunately out of the scope of the current work. Nonetheless, how the stress-response and 
inflammatory mediators might regulate the Kynurenine Pathway is of significant relevance. 
1.3 Stress, Inflammation and the Kynurenine Pathway 
The indoleamine and tryptophan 2,3-dioxygenases (DOs: Ido1, Ido2 and Tdo2) are rate-
limiting enzymes of the Kynurenine Pathway [28]–[31]. Tryptophan is metabolized via the 
Kynurenine Pathway for the production of NAD (Figure 2) [32]. Murine models of acute [33], 
[34] and chronic [34], [35] immunogenic sickness also exhibit increases in the Kynurenine 
Pathway activity. Likewise, stress increases brain [36]–[38] and plasma [36], [37], [39] 
kynurenine levels. 
Cells in the periphery (i.e. macrophages and dendritic cells) and in the brain (i.e. 
microglia, neurons, and astrocytes) expressing the DOs can metabolize tryptophan to 
kynurenine; however, kynurenine itself may not be neuromodulatory and is further 
metabolized, with cell-specific precision, into downstream neuroactive metabolites (or 
kynurenines, i.e. Kyns) [32]. For example, astrocytes mainly produce kynurenic acid (KynA), 
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which can be neuroprotective, while microglia and macrophages are enzymatically equipped to 
produce more neurotoxic 3-hydroxykynurenine (3-HK) and quinolinic acid (QuinA) (Figure 2) 
[32], [40].  
 
Figure 2. The Kynurenine Pathway of tryptophan metabolism. Tryptophan is 
an essential amino acid and therefore required from the diet. Greater than 90% 
of dietary tryptophan is metabolized via the Kynurenine Pathway. 
Astrocytes uptake Trp and Kyn [41] producing KynA [42], [43] which modulates 
cholinergic [44], [45] and glutamatergic [46], [47] synaptic transmission. Nonetheless, a balance 
of neurotoxic and neuroprotective kynurenines is evidently essential, as a hallmark of 
Schizophrenia is increased saliva, plasma, CSF and brain levels of KynA [48], [49]. Moreover, a 
KMO allele resulting in reduced KMO expression is associated increased CSF levels of KynA and 
psychotic features in bipolar disorder [50]. Although endogenous levels of KynA are possibly 
below those required for direct NMDA-R inhibition at the glycine site [47], KynA activates 
presynaptic neuronal α7nAChRs to reduced glutamate release [46]. KynA levels also modulate 
cortical acetylcholine release, presumably via α7nAChRs [44]. Kat2KO mice have 71% lower KynA 
in brain relative to WT mice, which was associated with increased glutamate levels and better 
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cognitive performance [47]. Nonetheless, although increased KynA may be associated with 
conditions such as bipolar disease and schizophrenia, increases in the microglial kynurenine 
QuinA [51] is more often associated with depression [52]. As such, KmoKO and HaaoKO mice are 
protected from some inflammation-induced depression-like behaviors [53]. Even so, whether 
increased KynA, QuinA, or increases in other Kyns mediate psychiatric symptoms is unknown, 
and as likely a scenario maybe that an imbalance in these Kyns also precipitate psychiatric 
symptoms by altering neurotransmission [54]. Nevertheless, the DOs are rate-limiting for the 
production of Kyns and their cell-type specific regulation in the brain remains ill defined.  
Of the DOs, Tdo2 is abundantly expressed in the liver relative to the brain [55] and 
hepatic Tdo2 mRNA is upregulated by acute stress [38], [56] or glucocorticoids [57]. Shimazu 
first reported increased hepatic Tdo2 activity (in vitro conversion of Trp→Kyn by liver 
homogenate) following peripheral administration of tryptophan, corticosterone, or following 
electric stimulation of the hypothalamic sympathetic nucleus [58]. Also, addition of 
dexamethasone (DEX, a synthetic glucocorticoid) to primary hepatocytes increases Tdo2 activity 
[59], [60] and Tdo2 mRNA [61], [62] expression. Thus, glucocorticoid regulation of hepatic Tdo2 
activity [63]–[65] is well accepted, and only recently has brain Tdo2 been associated with 
stress-induced depression-like behaviors [56]. Nonetheless, the cell-types expressing in the 
brain that respond to stress or inflammation with increased Tdo2 activity are poorly defined.  
Inflammation [33], [66]–[68] and stress [69]–[71] induce Ido1-dependent depression-
like behaviors. Inflammation-induced cytokines or stress-induced glucocorticoids promote 
depression-like behaviors such as increased immobility during the tail suspension (TST) or 
forced swim (FST) tests [33], [69], [71], [72], decreased sucrose preference [68], [71], [72] and 
diminished cognitive function [67], [72]. Following the intracerebroventricularly (i.c.v.) 
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administration of lipopolysaccharide (LPS, endotoxin, an immune system activator), Ido1 mRNA 
and mRNA for pro-inflammatory mediators tumor necrosis factor (TNF)α, interleukin (IL)-6, and 
inducible nitric oxide synthase (iNOS) are significantly unregulated in the hippocampus, but 
central interferon-(IFN)γ (a type II INF) mRNA is not detected [73], [74]. Likewise, Fujigaki et al. 
reported peripheral Ido1 induction by LPS largely depended on TNFα, and that both IFNγ- 
dependent and independent pathways exist [75]. LPS incubation increases Ido1 expression and 
enzymatic activity in primary microglia [76], and in organotypic hippocampal slice cultures 
(OHSC) [73], by time-dependent, and dose-dependent and IFNγ-independent mechanisms. 
These results are in contrast to the notion that IFNγ is a principal inducer of Ido1 [30], [77]. 
More importantly, since we know that kynurenine is transported across the blood-brain barrier 
[78], cellular origins of inflammation or stress-induced increases in Kynureinine Pathway activity 
within the brain remain poorly defined. 
There are considerable fewer studies investigating Ido2 than there are for Ido1. There is 
greater homology between human and mouse Ido2 proteins (84% similar) than human and 
mouse Ido1 proteins (77% similar) [79]. Ido2 is enzymatically active with 20% to 55% lower 
enzymatic activity than Ido1 [80], [81]. However, inhibiting Ido2 (siRNA) does not affect Ido1 
expression but still suppressed NAD production inducing apoptosis in melanoma cells [82]. 
Nonetheless, naïve Ido1KO mice have lower hepatic Ido2 expression, but Ido2KO mice have 
normal hepatic Ido1 expression [83]. This effect is certainly tissue-specific as the same study 
demonstrates that neither Ido1KO nor Ido2KO impacts the expression of the remaining Ido in 
spleen [83]. Indeed, there are several reports of perturbed Ido2 expression and inducibility in 
Ido1KO mice [84]–[86]; therefore, the role of Ido2 in mediating what are largely considered 
Ido1-dependent behaviors is likely underappreciated. 
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While only scantily covered within this thesis, the Kynurenine Pathway has other 
important functions aside from modulating neurotransmission. It is the major pathway for 
generating nicotinamide for NAD synthesis. Indeed, it is likely that plasma kynurenine is 
elevated by inflammation due to an increased demand of NAD for poly(ADP-ribosyl)ation 
mediated repair of DNA damage caused by reactive oxygen species (ROS) [87], [88]. 
Inflammation-induced increases in plasma kynurenine are likely derived from multiple tissues. 
In fact, kynurenine is also produced by IFNγ stimulated endothelial cells where it also acts as a 
vasodilator [89], and LPS-induced hypotension is less prominent in Ido1KO mice [89]. Ido1-
mediated immune suppression occurs via both enzymatic and non-enzymatic mechanisms [90]. 
Enzymatically, dendritic cells (DCs) upregulate Ido1 in response to IFNγ [91] or CTLA-4 [92] to 
deplete Trp in the cellular microenvironment resulting in suppressed T-Cell proliferation. DC 
activation of regulatory T-Cells (Tregs) is also Ido1-dependent, and Tregs also suppress T-Cell 
proliferation [93]. Ido1 also suppresses the anti-tumor response by producing kynurenine which 
activates the aryl hydrocarbon receptor (AhR) [94]. Thus, Ido1 blockade is an active areas of 
cancer research [95]. Ido1 enzymatic activity of hepatic stellate cells can induce Treg expansion 
via the T-cell AhR [96]. Establishing immune tolerance to LPS requires AhR activation, as well as 
Ido1 enzymatic activity and signaling [97]. DCs treated with TGFβ also promote Ido1-depenent T 
regulatory cell (Treg) expansion independently of Ido1 enzymatic activity [90]. Ido1 encodes 
two tyrosine-based inhibitory motifs (ITIMs) that can directly interact with SOCS3 to mediate 
ubiquitin-proteasome targeting of Ido1 [98]. These Ido1 ITIMs are phosphorylated in DCs 
following TGFβ, but not IFNγ treatments [90]. As opposed to Ido1, Ido2 has only one ITIM and is 
not targeted for SOCS3-mediated ubiquitination like Ido1 [99]. Thus, these studies suggest that 
Ido1 is generally immune suppressive by enzymatic and non-enzymatic pathways, and that Ido2 
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may have limited signaling potential by virtue of key Ido1 sequences not conserved. Ido2 also 
contributes to cancer pathogenesis independently of Ido1. Small interfering RNA (siRNA) 
knockdown of Ido2 arrested tumor growth while increasing ROS and cell apoptosis [82]. The 
results of specific siRNA-mediated Ido2 knockdown were reversible by exogenous NAD [82]. 
Since Ido1 expression was not disrupted by the siRNA, this demonstrated an Ido1-independent 
mechanism for Ido2 in cancer pathogenesis [82] further demonstrating their non-redundant 
function. Flow cytometry analysis of spleen cells from WT and Ido2KO animals found no 
differences in leukocyte counts [100], but Ido2KO mice have attenuated autoimmune arthritic 
disease, lower auto-antibody production, diminished CD4+ helper T-cell (Th) populations, and 
Th cytokine production compared to arthritic WT mice [83]. Indeed, mice treated with an 
antibody targeting the Ido2 protein also have inhibited autoimmune arthritis reactions relative 
to controls [101]. Taken together, these studies not only demonstrate the non-redundant 
physiology of Ido1 and Ido2, but also suggest that Ido2 may be generally more pro-
inflammatory, as opposed to Ido1 [30], [102]. 
During acute stress [103] and infection [104], [105], leukocyte reservoirs in bone 
marrow and spleen are mobilized. These immune cells traffic to multiple organs including the 
lung [104], liver and brain [105] where they may contribute to DO expression. While saline 
perfusion removes most monocytes from the lung tissue of animals treated with LPS [104], the 
net effects of cell trafficking on tissue-level DO expression is unrealizable without a more in-
depth investigation. Nonetheless, inflammatory mediators and glucocorticoids are known 
regulators of the rate-limiting DOs; defining and contrasting DO regulation in the periphery and 
brain may ultimately contribute to our understanding of the pathogenesis depression within 
the context of increased inflammation or perceived stress. Clearly, understanding cell-type 
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specific contributions to tissue level DO expression is essential. Here in we describe the 
astrocyte and microglia role played in the brains DO response to acute stress (Chapter 2), 
glucocorticoids and inflammation (Chapter 2), as well as behavioral effects of microglia and 
neuron derived Ido1 on inflammation induced depression-like behavior (Chapter 3).   
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CHAPTER 2: Glia- and tissue-specific regulation of Kynurenine Pathway 
dioxygenases by acute stress of mice 1 
2.1 Abstract 
Stressors activate the hypothalamic-pituitary-adrenal (HPA) axis and immune system 
eliciting changes in cognitive function, mood and anxiety. An important link between stress and 
altered behavior is stimulation of the Kynurenine Pathway which generates neuroactive and 
immunomodulatory kynurenines. Tryptophan entry into this pathway is controlled by rate-
limiting indoleamine/tryptophan 2,3-dioxygenases (DOs: Ido1, Ido2, Tdo2). Although implicated 
as mediating changes in behavior, detecting stress-induced DO expression has proven 
inconsistent. Thus, C57BL/6J mice were used to characterize DO expression in brain-regions, 
astrocytes and microglia to characterize restraint-stress-induced DO expression. Stress 
increased kynurenine in brain and plasma, demonstrating increased DO activity. Of three Ido1 
transcripts, only Ido1-v1 expression was increased by stress and within astrocytes, not 
microglia, indicating transcript- and glial-specificity. Stress increased Ido1-v1 only in frontal 
cortex and hypothalamus, indicating brain-region specificity. Of eight Ido2 transcripts, Ido2-v3 
expression was increased by stress, again only within astrocytes. Likewise, stress increased 
Tdo2-FL expression in astrocytes, not microglia. Interestingly, Ido2 and Tdo2 transcripts were 
not correspondingly induced in Ido1-knockout (Ido1KO) mice, suggesting that Ido1 is necessary 
for the central DO response to acute stress. Unlike acute inflammatory models resulting in DO 
induction within microglia, only astrocyte DO expression was increased by acute restraint- 
1 Edited from original publication with headings, figures, and tables renumbered:  
Dostal CR, Carson Sulzer M, Kelley KW, Freund GG & MCCusker RH. Glial and tissue-specific 
regulation of Kynurenine Pathway dioxygenases by acute stress of mice. Neurobiology of Stress. 7, 1-
15 (2017).  
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stress, defining their unique role during stress-dependent activation of the Kynurenine 
Pathway. 
2.2 Introduction 
An acute stress response is necessary for survival; it facilitates adaptation to external 
stressors and primes the body for the metabolic, physical and cognitive demands of fight-or-
flight [3]. Although classically assessed by HPA axis and sympathetic nervous system (SNS) 
activation, the stress response also involves precise changes in neuronal plasticity [3] along with 
central and peripheral immune activation [7], [24]. When the behavioral response to physical, 
psychological or metabolic stressors becomes maladaptive, profound consequences upsetting 
physical health and mental wellbeing occur [106]. Nearly half of Americans report experiencing 
at least one psychiatric disorder at some point in their lives, the most common being 
depression [107], [108]. Mounting evidence supports a causal link between stress-induced 
activation of the Kynurenine Pathway and psychiatric disorders, including depression [109]–
[111] and schizophrenia [48], [112]. Stress can also trigger depression, as well as influence the 
length and severity of depressive episodes [113]. Similarly, stress is a comorbid factor for 
schizophrenia [114]. Thus, advancing our understanding of the mechanism(s) by which the 
brain responds to stress serves to elucidate the biology underpinning stress-related psychiatric 
disease.  
Tryptophan (Trp) metabolism via the Kynurenine Pathway is initiated by three rate-
limiting dioxygenases, DOs [32]. Acute predatory stress [115], foot shock [37] and physical 
restraint or immobilization [56] increase DO activity and mRNA expression in the brain and 
liver. The general dogma is that glucocorticoids regulate Tdo2 expression, while Ido1 and Ido2 
are regulated by inflammatory mediators [32], [54]. Indeed, early work on stress and the 
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Kynurenine Pathway focused on the activation of hepatic Tdo2 (a.k.a. tryptophan pyrrolase) 
associated with HPA axis activation [58], [116]–[118]. Acute restraint-stress increases hepatic 
Tdo2 mRNA expression and activity [56] mediated in part by adrenocortical secretions [117]. 
Acute stress also increases Ido1 expression in the brain [39], [119] and periphery [39]. 
Nevertheless, there is only one report of stress regulating Ido2 expression in the CNS [120], 
although its unique role in immunophysiology is established [100].  
Stress is associated with immunological changes both in the periphery and CNS [7], 
[121]. Acute stress increases brain cytokine levels including TNFα[21], [22] and IL-1β[20], [122]. 
These cytokines synergistically regulate Kynurenine Pathway activity [75], [123]. The pro-
inflammatory effects of stress in the CNS is well established [7], [24] and it has been 
demonstrated that cytokine induction is necessary for Ido1 upregulation by stress [39], [71]. 
Although some work has investigated the regulation of DOs by stress within the CNS and 
periphery, the cellular origins responsible for DO induction remain undefined.  
Kynurenine itself is not considered a neuroactive metabolite [32], albeit increased DO 
activity is required for depression-like behaviors following stress [56], [71]. Instead, Kyn is 
further metabolized down the Kynurenine Pathway into other neuroactive metabolites, i.e. 
kynurenines. This is especially relevant to the CNS, owing to the remarkable cellular specificity 
in the production of kynurenines [32]. Most notably, astrocytes are enzymatically equipped to 
produce kynurenic acid (KynA) a glutamate (NMDA) and acetylcholine (α7nACh) receptor 
antagonist [42], [46], while microglia produce quinolinic acid (QuinA) and 3-hydroxykynurenine 
(3-HK) which are NMDA receptor agonists [51], [124]. A recent study found that chronic 
unpredictable stress increased central Ido1 and Tdo2 mRNA coincident with increased KynA 
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concentrations, but unchanged 3-HK [125]. This would suggest a specific role for astrocytes in 
stress-induced DO induction.  
Herein we report induction of all three DOs by acute restraint-stress specifically within 
astrocytes. We have expanded on recent work investigating DO-regulation by stress [119] to 
include the regulation of recently described alternatively-spliced DO mRNA transcripts [57], 
[126]. Moreover, since acute stress increases Kyn levels in both plasma and brain [36], [37], we 
include DO-regulation by stress in liver, the major tryptophan metabolizing organ primarily via 
Tdo2. Finally, since there is evidence of changes in Ido2 expression within Ido1-knockout 
(Ido1KO) mice [127], [128], we expanded our study to include stress-induced DO-regulation in 
brain, astrocytes and liver of Ido1KO mice. 
2.3 Methods  
Animals 
C57BL/6J (wild-type) or Ido1KO mice (The Jackson Laboratory, Bar Harbor, ME, USA) 
were used to establish breeding colonies to supply male mice for experiments. Mice were 
housed on a reversed 12 h light-dark cycle with ab lib access to food and water. Mice were 
individually housed at least 1 week prior to experiments. Mice were 14-15 weeks of age at the 
time of treatment. All animal procedures were approved by the Institutional Animal Care and 
Use Committee and performed in accordance with the Guide for the Care and Use of 





Restraint-stress was initiated at the onset of the dark cycle (10 am) and maintained for 3 
h using ventilated syringes [129]. Mice were euthanized 2 h after the cessation of restraint, at 
which time wild-type mice had a significant reduction in body weight associated with restraint-
stress (control change in body weight 0.1 ± 0.1 g vs. restrained -0.9 ± 0.1 g, p<0.001). A similar 
response was seen with Ido1KO mice (control 0.4 ± 0.1 g vs. restrained -0.7 ± 0.2 g, p<0.001). 
Following euthanasia, caval blood was collected into heparinized syringes. Samples were 
centrifuged and plasma collected. Mice were intracardially perfused using cold PBS plus 2 mM 
EDTA. After perfusion, samples were collected from separate cohorts of mice for either 1) 
whole brain sampling followed by glia enrichment or 2) brain region and liver collection as 
described in sections 2.2.2 and 2.2.3, respectively. 
Brain sampling and Glia enrichment: mouse cohort 1 
Brains were removed and placed in ice-cold Hank’s balanced salt solution then 
homogenized with a GentleMACS dissociator using Neural Tissue Dissociation kits (130-093-
231, Miltenyi Biotec Inc.) per manufacturer instructions. Immediately after homogenization, an 
aliquot of ‘brain’ was removed and stored in TRIzol (15596018, Ambion by Life Technologies) 
for later RNA isolation. The 'brain' samples were collected from homogenates before removal 
of astrocytes and microglia and thus represent expression by all cells and all brain regions in 
their original proportion. Remaining homogenate was demyelinated by centrifugation in 20% 
isotonic Percoll (E0414-1L, Sigma-Aldrich, St. Louis, MO). The cell pellet was re-suspended then 
partitioned into two fractions for positive-selection using either anti-Cd11b (130-093-634) or 
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anti-Glast labeling microbeads (130-095-826). Microglia (Cd11b+) and astrocytes (Glast+) were 
enriched using MACS MS magnetic separation columns. Microglia and astrocyte populations 
were suspended in TRIzol and stored at -80°C for later RNA isolation [130]. Glia enrichment was 
verified by comparing Glast1 and Cd11b mRNA expression to the 'brain' homogenate from 
which they were derived. Glast1 expression was greater in enriched astrocytes compared to 
brain in wild-type mice (5.9 ± 0.4-fold, p<0.001) and Ido1KO mice (12.0 ± 1.0-fold, p<0.001). 
Cd11b expression was greater in microglia preparations compared to brain from wild-type mice 
(265.6 ± 10.8-fold, p<0.001). 
Brain region and liver collection: mouse cohort 2 
Brain-regions (prefrontal cortex (PFC), striatum (Stri), hippocampus (Hippo), 
hypothalamus (Hypo)) and livers were collected and frozen for later RNA extraction. The 
remaining brain (sans PFC, Stri, Hippo and Hypo) was frozen for analysis of Kyn. 
Gene Expression by qPCR 
RNA was extracted from brain, astrocytes, microglia, PFC, Stri, Hippo, Hypo and liver, 
then reverse-transcribed (4368813, Applied Biosystems). Resulting cDNA was used for 
quantitative polymerase chain reaction (qPCR) using TaqMan Universal PCR Master Mix 
(4324020, Applied Biosystems). Expression of each test gene were normalized to the reference 
gene (Gapdh) using the 2-ΔΔCt method [131]. Gene expression in naïve control (Ctrl) brain or Ctrl 
PFC is set to 1.0, with samples from the same experiments expressed relative to appropriate 
controls. Gene structure and mRNA transcripts for the DOs are shown in Figure 3. Assays 
designed to quantify the various DO transcripts are described in Table 1. PCR was performed 
with probe-based assays (IDT, Coralville, Iowa). Custom assays were designed using the IDT 
PrimerQuest® Design Tool. Assays for Kat2 (Mm.PT.49.16077568), Kmo (Mm.PT.56.31570400), 
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Kynu (Mm.PT.56.12643855) and Haao (Mm.PT.58.29327685) were predesigned by IDT. Because 
of low expression, some transcripts are 'not detected' (i.e. Ct values ‘undetermined’) thus 
preventing calculation of relative gene expression following induction; for analysis a Ct value of 
40.0 is assigned when this occurs. 
 
Figure 3. Gene structure and transcripts for murine Ido1, Ido2 and Tdo2. Like human DOs, murine DO gene-
processing results in the expression of multiple mRNA transcripts. Our previous (Brooks et al., 2016a, 2016b) and 




Table 1: Assay specifics for analysis of murine Ido1, Ido2 and Tdo2 steady-state gene expression. 
Ido2-v5 and Ido2-v6 sequence lie within Ido2/v2 (thus it is not possible to design an assay specific to 
Ido2-v5 or Ido2-v6 that does not also quantify Ido2-v2). We have data indicating distinct differences in 
the regulation of these three transcripts [126]. Tdo2-FL's complete sequence lies within Tdo2-v1 (thus it 
is not possible to design an assay specific to Tdo2-FL that does not also quantify Tdo2-v1). Our current 
and published [57], [126] data show distinct differences in the expression and regulation of Tdo2-FL and 
Tdo2-v1, indicating that they are distinctly expressed transcripts. Names for Ido2-v3:∆4, Tdo2-FL/-v1/-v2 
and Tdo2 exon 0a and 0b exon designations are shown in an attempt to agree with published 
nomenclature [55], [100]. Specifics shown for each qPCR assay include transcript location, catalog 
numbers (Mm.PT…) or our custom assay names, primer/probe sequences and confirmed amplicon sizes.  
Table 1. Assay specifics for analysis of murine Ido1, Ido2 and Tdo2 steady-state gene expression. 
Transcript Exon Span Key Catalog # or assay name  Primer/Probe Sequence Amplicon, bp 
Ido1-FL 1-3-4  Mm.PT.42.8645095 Forward TTTGCTCTACCACATCCACTG 117 
    Probe 6-FAMCAGATTTCTZenAGCCACAAGGACCCAGGIABkFQ  
    Reverse GCAGCTTTTCAACTTCTTCTCG  
       
Ido1-v1 2-3  Ido1-v ex 2-3 Forward GACCCCGGACGGTAAAATTAT 138 
    Probe 6-FAMTCGGGCAGCZenTCCACATTACAATTCAIABkFQ  
    Reverse TCTCAATCAGCACAGGCAG  
       
Ido1-v2 2b-3-4-5  Ido1-X2-mouse Set 1  Forward CGGACGGTGGAGCTG 256 
    Probe 6-FAMATTGAGAACZenGGGCAGCTTCGAGAAIABkFQ  
    Reverse CGCAGTAGGGAACAGCAATA  
Ido2-FL 1-2-4  Mm.PT.42.8856312 Forward GGAGATACCACATTTCTGAGGA 114 
    Probe 6-FAMCCAGAGGATZenTTGGAAGGAGAAAGCCATIABkFQ  
    Reverse CGATTAAGTGAGGAAGTCTGAGG  
       
Ido2-v1 3-4  Ido2-v ex 3-4 Forward GGACTTTACATCCCTAACCTCAC 131 
    Probe 6-FAMCCTCAGCTTZenCTCGAACCCTGTAACTGTAIABkFQ  
    Reverse CTGCTCACGGTAACTCTTTAGG  
       
Ido2-v2 3'-4  Ido2-X4 Set 4  Forward AAGCCTGCGGAGCAAAG 88 
   Ido2-X2-mouse Set 1 Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ  
   Ido2-v2-ex3-4 set2 Reverse GAGGCATCTGTCCTGCCT  
       
Ido2-v3 4-5'-6-7  Ido2-v4-Mz Set1  Forward CCCCAAAAGGTATCCAGGAACT 107 
    Probe 6-FAMCTGACCTGGZenTGCTGACAAACTGGAIABkFQ  
    Reverse ACTGATTTCCAACGGTCCTTCT  
       
Ido2-v4 +1-4-5  Ido2-X1b-mouse Set 2 Forward CCAAATCCTCTGATGCCTCTC 148 
    Probe 6-FAMTAAAGAGTTZenACCGTGAGCAGCGCCIABkFQ  
    Reverse AAAGGTGCTGCCAAGATCTC  
       
Ido2-v5 3"-5  Ido2-X2-mouse Set 1 Forward AAGCCTGCGGAGCAAAG 244/253 
    Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ  
    Reverse CCAAGTTCCTGGATACCTCAAC  
       
Ido2-v6 +3'-4  Ido2-v2-ex3-4 set2  Forward GAGCTGAAGAGATGAGCAATGA 85/85 
    Probe 6-FAMAGGACAGATZenGCCTCTCCTGGACTIABkFQ  
    Reverse ACGGTAACTCTTTAGGAATCTGC  
       
Ido2-v7 4+-5  Ido2-v1-ex4'-5 set1 Forward AGGTTCCGTTGCCTAGTTTC 101 
    Probe 6-FAMAAGAGGGTGZenCTGCCAAGATCTCTTIABkFQ  
    Reverse CCAAGTTCCTGGATACCTCAAC  
       
Ido2-v8 +1-2  Ido2-X5 Set 1 Forward CCTCAGGGCAAGGTTCTC 294 
    Probe 6-FAMACCGCACAAZenGTACAACCACACAGAIABkFQ  
    Reverse CTGGCGGTTCTCGATTAAGT  
Tdo2-FL 1-2  Mm.PT.42.9084201.g Forward CCTGAGACACTTCAGTACTATGAG 99/99 
    Probe 6-FAMCCCGTTTGCZenAGGAAACAGTGTAGGAIABkFQ  
    Reverse CTGTCTTCTTCATTGTCCTCCA  
       
Tdo2-v1 0a-0b-1  Tdo2 variant1 exons 0a 0b-1.2 Forward CCAGTACGAAATGAGATCCGG 132 
 1-2  Mm.PT.42.9084201.g Probe 6-FAMAGACACAGCZenCAATCAGCACCCAIABkFQ  
    Reverse AGGTTTGCTAGGTCAGGAATG  
       
Tdo2-v2 0a-2  Tdo2 variant2 exons 0a 1.2 Forward GAAATGAGATCCGGGCTAAGAG 78 
    Probe 6-FAMTGGGTGCTGZenATTGGCTGTGTCTIABkFQ  




Kynurenine levels by high performance liquid chromatography (HPLC) 
Brain samples were suspended in ice cold buffer (0.1 N perchloric acid + 25 μM ascorbic 
acid) at 200 mg wet weight/ml and disrupted by sonication. Samples were incubated for 30 min 
then centrifuged at 12,000 g for 5 min at 4°C. Supernatants were collected and loaded into 
Spin-X filters (Corning, NY, USA) and centrifuged at 10,000 g for 5 min at 4°C. Filtrates were 
used for HPLC analysis. Plasma samples were processed for analysis by HPLC as previously 
reported [132]. HPLC mobile phase consisted of 75 mM monosodium phosphate (pH 4.6), 25 
μM EDTA and 0.01% triethylamine prepared in either 4.5 or 6% acetonitrile for brain and 
plasma extracts, respectively. Chromatogram peaks were integrated using EZChrom SI software 
(Agilent Technologies, Santa Clara, CA, USA). Kyn standards were made to encompass levels in 
the samples.  
Statistics 
Two-way ANOVA was used to compare the relative expression of genes between 
astrocytes, microglia and brain, and to compare brain-regions and liver, while T-tests were used 
to determine the effects of stress. Analysis was performed using SigmaPlot 14.0 software. 
Significance was set at p≤0.05. 
2.4 Results 
Acute stress increases gene expression of markers for HPA axis activation and 
inflammation 
FK506-binding protein 51 (Fkbp51) expression was increased by restraint-stress in both 
brain and liver (Figure 4A). These data confirm a HPA axis response [133], [134]. Some effects of 
restraint-stress are mediated by increases in pro-inflammatory cytokines. Restraint-stress 
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increased IL-1β (Figure 4B) and TNFα (Figure 4C) expression within brain, confirming an 
inflammatory response. Although relative expression of IL-1β and TNFα was higher in liver vs. 
brain, a stress-induced inflammatory response was not observed in liver. Also, IFNγ gene 
expression was unaffected by restraint-stress in brain and liver. IFNγ protein concentrations in 
plasma from naïve and restrained mice were below detection-limits (data not shown). 
 
Figure 4. Acute stress increases gene expression of markers for stress and 
inflammation. Perfused brain and liver tissue obtained from wild-type (WT) 
control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h 
restraint were used to assess (A) HPA activation by quantifying Fkbp51 
expression and an inflammatory response by quantifying (B) IL-1β and (C) TNFα 
expression. *p<0.05 Ctrl vs. Res. 
Acute stress increases plasma and brain kynurenine in wild-type, but not Ido1KO mice 
Plasma concentrations of Kyn were increased by restraint-stress in wild-type, but not 
Ido1KO mice (Figure 5A). Brain concentrations of Kyn were also increased by stress in wild-type, 
but not Ido1KO mice (Figure 5B). Since the DOs are rate-limiting enzymes in the metabolism of 
Trp to Kyn [32], these data verify restraint-stress activation of the Kynurenine Pathway and the 




Figure 5. Acute stress increases plasma and brain kynurenine in wild-type, but 
not Ido1KO mice. Two hours after a three hour restraint-stress (A) plasma and 
(B) brain from WT and Ido1KO mice were analyzed for kynurenine (Kyn) by 
HPLC. *p<0.05 comparing control (Ctrl) to restraint-stress (Res) samples. 
Acute stress increases Ido1-v1 expression in astrocytes and select brain-regions 
Ido1 expression in the mouse brain is reported to both increase and remain unchanged 
following acute stress. Based on our nomenclature (Figure 3), these studies used PCR assays 
amplifying either Ido1-FL [39], [120] or all Ido1 transcripts simultaneously, Ido1-Tot [56]. We 
independently quantified expression three Ido1 transcripts to refine this issue. In agreement 
with our previous work [57], Ido1-FL and Ido1-v2 transcripts were poorly expressed in brains 
and livers of naïve mice. Their expression was not induced by restraint-stress (data not shown). 
Ido1-v1 is well expressed in the mouse brain and numerically, but non-significantly, 
elevated by restraint-stress (Figure 6). Initially, this suggests that Ido1-v1 expression is not 
altered by restraint-stress; however, a more in-depth investigation reveals the nature of Ido1-
v1 expression. Ido1-v1 expression is induced 4.8-fold in astrocytes, but not in microglia, isolated 
from stressed mice. The stress effect is not only cell-type specific but brain-region specific, 
disguising significant effects when whole-brain is assessed. Ido1-v1 expression was highest in 
striatum followed by hypothalamus relative to other brain-regions. Restraint-stress increased 
Ido1-v1 in prefrontal cortex and hypothalamus. As expected, Ido1KO mice did not express Ido1-
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v1 (Figure 6), Ido1-FL or Ido1-v2 (not shown). Hepatic expression of Ido1-FL, Ido1-v1 and Ido1-
v2 was low and not altered by stress. Thus, Ido1 expression exhibits brain-region, glial and 
transcript-specificity within naïve and restrained wild-type mice. 
 
Figure 6. Acute stress increases Ido1-v1 expression in astrocytes and select 
brain-regions. Tissue and glia from control (Ctrl) and restraint-stressed (Res) 
mice sacrificed 2 h after a 3 h restraint were analyzed for Ido1-v1 expression. 
Expression was quantified in whole-brain, glia, liver and several brain-regions: 
the prefrontal cortex (PFC), striatum (Stri), hippocampus (Hippo) and 
hypothalamus (Hypo). Samples from Ido1KO mice did not express any Ido1 
transcript. Ido1-FL and Ido1-v2 transcripts were not detected by qPCR. *p<0.05 
comparing Ctrl to Res within tissue or glia. φp<0.05 compared to other brain-
regions. 
Acute stress increases Ido2-v3 expression in astrocytes 
To our knowledge, there is only one report examining the effect of stress on Ido2 
expression. Using an assay that detects all transcripts (Ido2-Tot), forced-swimming-associated 
stress increased hippocampal Ido2 expression in BALB/c, but not C57BL/6J, mice [120]. We 
quantified expression of Ido2 (Figure 3) for transcript-, tissue- and glial-specific responses 
between naïve and restrained mice. Of eight Ido2 mRNA variants, restraint-stress remarkably 
increased the expression of only one Ido2 transcript; this transcript-specificity would make it 
difficult to detect changes when simultaneously quantifying all transcripts, i.e. Ido2-Tot. 
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Ido2-FL is poorly expressed in the naïve mouse brain except within the striatum where 
Ido2-FL expression is 10-fold higher (Figure 7A) than other brain-regions. In striking contrast, 
hepatic Ido2-FL is markedly higher in relation to brain-regions. While restraint-stress had no 
effect on central Ido2-FL, hepatic Ido2-FL expression in wild-type and Ido1KO mice was 
decreased following restraint. 
Ido2-v3 is well expressed in the mouse brain, but stress-induced changes are not 
realized when analyzing whole-brain or brain-regions (Figure 7B). The low basal expression in 
astrocytes and microglia relative to brain indicates that most of the Ido2-v3 in naïve brain is 
expressed by stress-insensitive cells. Nonetheless, Ido2-v3 expression is increased by stress 13-
fold in astrocytes. In Ido1KO mice, Ido2-v3 expression by astrocytes is not increased by stress. In 
wild-type mice, hepatic expression of Ido2-v3 is greater relative to brain-regions; and hepatic 
Ido2-v3 is decreased by stress, albeit significant only for Ido1KO mice. 
Ido2-v4 is also poorly expressed in the naïve mouse brain except within the striatum 
(Figure 7C) where Ido2-v4 expression is highest [57]. Again, hepatic expression of Ido2-v4 is 
markedly higher in relation to brain-regions. While not regulated by stress within the brain, 
stress decreased hepatic Ido2-v4 expression in wild-type and Ido1KO mice. 
Thus, expression of Ido2-FL, Ido2-v3 and Ido2-v4 are stress sensitive, lowered in liver 
and Ido2-v3 is elevated in astrocytes. Other Ido2 transcripts exhibit unique patterns of 
expression across tissues and brain-regions, but their expression is relatively independent of 
stress (Figure 8). 
Compared to wild-type mice, the brains of Ido1KO mice are strikingly deficient in several 
Ido2 transcripts, including 78% reduction in Ido2-v3 (Figure 7B), 84% reduction in Ido2-v1, 92% 
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reduction in Ido2-v2, 22% reduction in Ido2-v5, 57% reduction in Ido2-v6 and loss of detectable 
Ido2-v7 (Figure 8). This loss of Ido2 in Ido1KO is cell- and tissue-specific, and was previously 
reported to occur in B-lymphocytes, but not liver [100]. We confirm their finding showing that 
relative expression of various Ido2 transcripts is similar in the liver between wild-type and 
Ido1KO mice (Figure 7 and Figure 8). The decrease in Ido2-v3 within brains of Ido1KO mice is not 
mediated astrocytes, as Ido2-v3 in astrocytes from Ido1KO mice is numerically greater than 
astrocytes from wild-type mice. Thus, loss of Ido2-v3 occurs in another cell-type within the 
brain. Additionally, although Ido2-v3 is induced by stress in astrocytes from wild-type mice, it 
was not increased in Ido1KO mice. Thus, the regulation of Ido2 is transcript-, tissue- and cell-
type-specific in wild-type mice, and genetic deletion of Ido1 perturbs central Ido2 expression. 
Importantly, when interpreting physiologic differences between wild-type and Ido1KO mice, 




Figure 7. Acute stress increases Ido2-v3 expression in astrocytes. Tissue and 
glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 
h restraint were analyzed for (A) Ido2-FL, (B) Ido2-v3 and (C) Ido2-v4 
expression. *p<0.05 comparing Ctrl to Res within tissue or glia. φp<0.05 




Figure 8. Additional Ido2 transcripts and their expression following acute stress. Tissue and glia 
from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were 
analyzed for additional Ido2 transcripts. (A) Ido2-v1 expression in brain is greater than astrocyte 
and microglia levels, indicating these cell-types are not the major source of Ido2-v1. 
Hypothalamic Ido2-v1 expression was greater than all other brain-regions. Stress slightly 
decreased Ido2-v1 relative to controls in the striatum. Ido2-v1 expression was not detectable in 
the liver. (B) Ido2-v2 expression was greater in microglia than brain with brain and astrocytes 
having similar expression levels, indicating that microglia and astrocytes are a major source of 
central Ido2-v2. In Ido1KO mice, Ido2-v2 was greater in astrocytes compared to brain, and 
increased following restraint-stress relative to Ctrl. Within brain-regions, Ido2-v2 expression 
differed with Hypo > PFC = Stri > Hippo > liver. Hypo Ido2-v2 was increased ~28% by stress 
relative to Ctrl. (C) Ido2-v5/v2 expression did not differ in brain, astrocytes or microglia of Ctrl or 
stressed mice, indicating a uniform expression pattern for this transcript. Ido2-v5/v2 expression 
in the hypothalamus was greater than all other brain-regions. Hepatic Ido2-v5/v2 expression was 
not detected. Ido2-v5/v2 expression was not detected in brain or astrocytes of Ido1KO mice. (D) 
Brain Ido2-v6/v2 expression was greater than astrocyte and microglia, indicating these cell-types 
are not the major source of brain Ido2-v6/v2. In Ido1KO mice, brain Ido2-v6/v2 expression was 
also greater than astrocyte levels. Ido2-v6/v2 expression was greater in Hypo than all other 
brain-regions. Hepatic Ido2-v6/v2 was not detectable. (E) Ido2-v7 expression did not differ in 
brain, astrocytes or microglia of Ctrl or stressed mice or across brain-regions, indicating a uniform 
expression pattern for this transcript. Ido2-v7 was not detected in Ido1KO mice brain or 
astrocytes. Hepatic Ido2-v7 expression levels were greater than all other brain-regions. (F) Ido2-
v8 expression was only detected in liver. *p<0.05 comparing Ctrl to Res samples within tissue or 
glia. φp<0.05 compared to other brain-regions. δp<0.05 liver compared to all brain-regions. 
Overall these additional Ido2 transcripts are relatively impervious to stress. However, Ido2 
transcripts fall into two general categories: 1) hepatic expression > than brain (Ido2-FL, Ido2-v3, 
Ido2-v4 (Figure 7), Ido2-v6 and Ido2-v8 (Figure 8)); 2) brain expression > than liver (Ido2-v1, Ido2-
v2, Ido2-v5 and Ido2-v7 (Figure 8)). This illustrates a distinct regulatory mechanism driving the 
expression of Ido2, albeit with as yet unrecognized functional consequences. 
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Acute stress increases Tdo2-FL expression in brain, astrocytes and liver 
Tdo2 was the first DO investigated within the context of acute stress, with early reports 
describing increases in hepatic Tdo2 activity [117], [135], [136]. However, Tdo2 expression in 
the frontal cortex of the rat brain was unchanged after acute stress despite an increase of Tdo2 
in liver using a qPCR assay that quantified all Tdo2 transcripts, i.e. Tdo2-Tot [56]. The current 
report is the first to quantify the regulation of the three known Tdo2 transcripts (Figure 3) in 
stressed mice to identify distinct regulatory profiles. 
Tdo2-FL expression is increased to 2.3-fold of controls in brain by restraint-stress (Figure 
9A). This effect is paralleled by a 1.8-fold increase within astrocytes. Tdo2-FL expression in 
microglia is lower than brain and astrocytes and unaffected by stress. Tdo2-FL expression within 
astrocytes from Ido1KO mice was also doubled by restraint-stress, but not within the brains from 
which they were derived. Astrocyte Tdo2-FL expression is greater in Ido1KO mice compared to 
the brain of wild-type mice, suggesting genetic deletion of Ido1 results in specific compensatory 
Tdo2-FL upregulation within astrocytes. Although stress increased Tdo2-FL expression in brain 
from wild-type mice, stress did not increase Tdo2-FL in brain of Ido1KO mice. This finding 
suggests another brain cell-type, possibly neurons [54], expressing Tdo2-FL is only stress-
sensitive when Ido1 is intact. Tdo2-FL is considerably higher in the liver relative to brain-regions 
and increased by stress in both wild-type and Ido1KO mice. 
Tdo2-v1 is increased to 10.1-fold of controls by restraint-stress in brains from wild-type 
mice (Figure 9B). Although Tdo2-v1 expression is greater in astrocytes and microglia relative to 
whole-brain, its expression in these cells is unaffected by restraint. These data suggest the 
stress-induced increase in brain Tdo2-v1 is mediated by neurons (or other glia) which also 
express Tdo2 [54]. Unlike Tdo2-FL, Tdo2-v1 expression is similar across brain-regions. Thus, 
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these data illustrate a unique expression pattern vs. Tdo2-FL (despite the entire Tdo2-FL 
sequence encompassed within Tdo2-v1, Figure 3). Like Tdo2-FL, there is no increase in brain 
Tdo2-v1 expression in Ido1KO mice, indicating a requirement of Ido1 for brain Tdo2-v1 
induction. In wild-type mice, hepatic Tdo2-v1 expression is greater than in brain-regions, but 
not significantly affected by restraint-stress.  
Tdo2-v2 expression in brain of wild-type mice is increased 7.3-fold by restraint-stress 
(Figure 9C). Tdo2-v2 expression in both astrocytes and microglia is greater than brain levels, yet 
unaffected by restraint. Like Tdo2-v1, these data suggest the stress-induced increase in brain 
Tdo2-v2 is mediated by neurons or other glia. Tdo2-v2 expression in astrocytes from Ido1KO 
mice is decreased slightly but significantly by restraint. Tdo2-v2 expression is similar across 
brain-regions. In wild-type mice, Tdo2-v2 levels in liver were greater than brain-regions and 
increased by restraint. 
Therefore, all three Tdo2 transcripts are increased by restraint-stress in brains of wild-
type mice. The increase in brain Tdo2-FL parallels the increase in astrocytes, whereas the 
increases in Tdo2-v1 and Tdo2-v2 are mediated by unidentified cell-types. Only Tdo2-FL and 
Tdo2-v2 are increased by restraint-stress in liver relative to control mice. Thus, there is 




Figure 9. Acute stress increases Tdo2-FL expression in liver, brain and 
astrocytes. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice 
sacrificed 2 h after a 3 h restraint were analyzed for (A) Tdo2-FL/v1, (B) Tdo2-v1 
and (C) Tdo2-v2 expression. *p<0.05 comparing Ctrl to Res within tissue or glia. 





Other Kynurenine Pathway related gene expression & regulation by stress 
The DOs are rate-limiting for Trp to Kyn metabolism, but Kyn itself is further 
metabolized into neuro- and immune-active kynurenines in a cell-specific manner. This 
specificity is achieved by differential expression of enzymatic machinery downstream of the 
DOs [29]. Thus, we expanded our analysis to include enzymes further along the Kynurenine 
Pathway. 
Kat2 (kynurenine-2-oxoglutarate aminotransferase) converts Kyn to KynA. Kat2 
expression is enriched in astrocytes compared to microglia and highly expressed in liver. Within 
brain regions, Kat2 expression is highest in the hypothalamus; however, Kat2 expression is 
unaffected by stress (Figure 10A). These data confirm previous reports of astrocyte enrichment 
[47], [137], [138]. 
Kynu (kynureninase) initiates Kyn metabolism to QuinA. Kynu expression is greater in 
microglia relative to astrocytes and considerably higher in liver (Figure 10B). These data 
confirming previous reports of microglial enrichment of this enzyme within the brain [42], 
[139]. Kynu expression is highest in the hypothalamus with expression largely unaffected by 
stress, the exception being a decrease in the hippocampus. 
Kmo (kynurenine 3-monooxygenase) also initiates Kyn metabolism to QuinA. Kmo 
expression is greater in microglia relative to astrocytes, but again considerably higher in liver. 
These data confirm previous reports of microglial enrichment of this enzyme in the brain [42], 




Haao (3-hydroxyanthranilate 3,4-dioxygenase) acts downstream of Kynu and Kmo to 
complete QuinA synthesis. Haao expression is greater in microglia relative to astrocytes, but 
again considerably higher in liver. Haao expression is slightly but significantly decreased by 
stress in both microglia and liver (Figure 10D). Again, these data confirm preferential expression 
of Haao by microglia in the brain [42], [51]. 
The extremely high levels of Tdo2, Ido2 and especially the downstream enzymes within 
the liver (relative to brain), attest to its ability to efficiently generate niacin and NAD [140]. 
Overall, since the DOs are considered rate-limiting in the Kynurenine Pathway, these changes in 
downstream enzymes probably do not result in an overall shift in the relative ability to produce 
downstream kynurenines; that is to say astrocytes will generate primarily KynA and microglia 




Figure 10. Other Kynurenine Pathway related gene expression & regulation by stress. 
Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 
3 h restraint were analyzed for (A) Kat2, (B) Kynu, (C) Kmo and (D) Haao expression. 
*p<0.05 comparing Ctrl to Res within tissue or glia. φp<0.05 compared to other brain-




Acute restraint-stress increased the expression of all three DOs within the mouse brain 
in a transcript-, tissue- and cell-type specific manner. Brain and plasma levels of Kyn were 
increased in stressed mice relative to controls demonstrating a functional increase in DO 
activity following acute restraint-stress. Remarkably, Ido1-v1, Ido2-v3 and Tdo-FL expression 
was increased by stress in astrocytes, but not microglia. However, in comparison to wild-type 
mice, we found aberrant Ido2 and Tdo2 expression in Ido1KO mice demonstrating a necessity of 
Ido1 for normal Ido2 and Tdo2 regulation within the brain. The expression patterns of 
downstream Kynurenine Pathway enzymes support the hypothesis that astrocytes are central 
producers of KynA while microglia are equipped to produce primarily QuinA. Since only 
astrocyte DO expression was increased by stress, these finding further implicate a key role for 
Kyn and KynA within the neurobiology of stress-induced behaviors. 
Acute stress increases gene expression of markers for stress and inflammation 
The induction of Fkbp51 by restraint-stress in brain and liver (Figure 4A) confirm 
glucocorticoid receptor activation [133], [134]. However, restraint-stress increased brain, but 
not liver, expression of pro-inflammatory cytokines, Tnfα and IL-1β (Figure 4B-C), confirming 
previous reports of increases in brain IL-1β [20], [122] and circulating TNFα and IL-1β following 
stress, without coincident changes in the liver [38]. While both the HPA axis and autonomic 
nervous system contribute to the induction of peripheral and central pro-inflammatory 
cytokines following stress [7], [24], the pro-inflammatory cytokines TNFα [26] and IL-1β [25] 
also increase glucocorticoid release. Extending our understanding by which inflammatory 
mediators are regulated by the stress response (or vice versa) is out of the scope of this study; 
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however, we are interested in how these confirmed stress responses affect the Kynurenine 
Pathway.  
Acute stress increases plasma and brain kynurenine in wild-type, but not Ido1KO mice 
Following acute stress, increases in central and peripheral Kyn concentrations have been 
independently verified [36]–[39], [115], [141]. Our data reaffirm acute-stress increases both 
brain and plasma Kyn and further demonstrates the necessity of Ido1 for restraint-stress-
induced increase in Kyn (Figure 5A-B). Although Ido1 is intimately involved in elevated Kyn 
levels associated with inflammation [33], Ido2 and Tdo2 also have this capability [54]. Thus, the 
inability of stress to induce Ido2-v3 and Tdo2 variants in Ido1KO mice may also be involved in the 
lack of Kyn induction in Ido1KO mice. 
Acute stress increases Ido1-v1 expression in astrocytes and select brain-regions 
Ido1 expression is increased by inflammatory mediators [32], [57], [76] and 
synergistically by inflammatory mediators plus corticosteroids, although in a transcript-specific 
manner [57]. Within the brain and liver of naïve mice, Ido1-FL and Ido1-v2 expression was 
extremely low, similar to our previous report [57]. Ido1-FL and Ido1-v2 expression were not 
increased by restraint-stress in the current study; however, a previous study observed a 14-fold 
increase in whole-brain Ido1-FL following acute combined acoustic and restraint-stress of 
female BALB/c mice [39]. Whether the difference between that of Kiank and our study is due to 
a stronger stressor (acoustic+restraint vs. restraint), different mouse strain (BALB/c vs. 
C57BL/6J) or sex (female vs. male) is open to debate. Basal Ido1 expression by astrocytes from 
BALB/c mice may be greater than that of C57BL mice, permitting detection of Ido1 induction in 
whole brain by stress. Independent of this, Ido1-FL and Ido1-v2 are inducible in vivo by 
inflammatory signals such as LPS [33], [126] and Ido1-FL induction in the mouse brain by 
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mycobacterium infection is IFNγ-dependent [142]. Since IFNγ was not increased in our acute-
stress model, Ido1-FL was not induced. Thus, our data clearly suggest that neither Ido1-FL nor 
Ido1-v2 mediate the stress-induced Kyn levels in the brain of C57BL/6J mice. 
Ido1-v1 is the major Ido1 transcript within the naïve mouse brain, and its expression is 
increased by LPS in vivo [126] and IFNγ ex vivo [57]. IFNγ also induces Ido1-Tot expression in 
astrocytes [102] and microglia [143]. However, the current data suggest IFNγ-independent 
stimuli must be responsible for Ido1-v1 induction in astrocytes by stress. Although Ido-v1 was 
not increased by stress in whole-brain, its expression was increased by stress in the frontal 
cortex and hypothalamus (Figure 6), likely within astrocytes. The significance of the cortex and 
hypothalamus sensitivity to restraint-induced Ido1-v1 induction relative to behavior remains to 
be determined. 
Astrocytes are a heterogeneous population of related cells [144] varying in functionality 
across brain-regions [145]. Previous reports assessing Ido1-Tot indicated primary cultures of 
murine astrocytes do not express Ido1 [102]. By contrast, we detected Ido1-v1 expression in 
freshly isolated astrocytes, albeit at lower levels compared to the brains from which they were 
isolated. Thus, the distribution of Ido1 transcripts is cell-type specific. Astrocytes are not the 
major source of central Ido1-v1, but a 4.8-fold induction by stress could be critical to changes in 
astrocyte Kyn and KynA production. 
We detected minimal expression of Ido1 transcripts in liver which were unaffected by 
restraint-stress; however, Ohta found increased hepatic Ido1-Tot following 6 h of water-
immersion restraint-stress. This was associated with increased hepatic and serum IFNγ [38]. 
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Thus, it is possible that our acute stress was insufficient for inducing IFNγ necessary for hepatic 
Ido1 induction. 
Acute stress increases Ido2-v3 expression in astrocytes 
Ido2 expression in the brain and liver is consistent with our previous report [57]. For 
example, Ido2-FL is enriched in the striatum, yet its expression is highest in liver (Figure 7A). 
Sets of Ido2 transcripts share expression patterns: Ido2-FL and Ido2-v4 are enriched in striatum, 
while Ido2-v1, Ido2-v2, Ido2-v3, Ido2-v5 and Ido2-v6 are enriched in hypothalamus, but Ido2-v8 
was not detected in the brain (Figure 7 and Figure 8). The cell-types responsible for these 
differences are unknown. Cells within distinct brain-regions must either differently splice Ido2 
pre-RNA to generate different transcripts or utilize different promoter regions to initiate 
transcription thereby generating different transcripts. The same can be said for Ido1 and Tdo2 
transcript profiles, albeit Ido2 is the most complex. 
Mazarei found enriched expression of both Ido1-Tot and Ido2-Tot in striatum and that 
Ido1KO mice were deficient in Ido2-Tot within the striatum [85], reflecting our expression 
pattern for Ido1-v1 or Ido2-FL, Ido2-v4 and Ido2-v6, respectively (Figure 6, Figure 7 and Figure 
8). Moreover, unlike wild-type mice, Ido2-v3 expression was not increased by stress in Ido1KO 
mice (Figure 7B), further highlighting the dysregulation of Ido2 within the brain in the absence 
of Ido1. These findings raise the issue as to whether behavioral changes seen with Ido1KO mice 
may also be dependent on reduced basal Ido2 expression and the non-inducible nature of Ido2 
in Ido1KO mice. This is important, as Ido1 is considered anti-inflammatory, whereas Ido2 acts as 
a pro-inflammatory facilitator most likely via an enzymatic-independent mechanism [146]. 
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Astrocytes and microglia also differentially express Ido2 transcripts. Ido2-v3 (Figure 7B) 
was the only Ido2 transcript upregulated by stress and this only occurred within astrocytes. 
When cloned and overexpressed, the enzymatic activity of the protein encoded by Ido2-v3 was 
less than that from Ido2-FL [100]. Thus, the enzymatic or non-enzymatic role that stress-
responsive Ido2-v3 plays in animal behavior, brain function and Kyn production remains to be 
determined. 
In the current study, both astrocytes and microglia were found to express all three DOs, 
albeit to varying degrees. However, the DOs may not be universally co-expressed. As an 
example, within the liver Ido2 and Tdo2 are constitutively expressed by mature hepatocytes 
[128], [147], whereas low but interferon-γ-inducible Ido1 expression is found within hepatic 
stellate cells [96]. This pattern may explain the abundant relative expression of Ido2 and Tdo2 
compared to Ido1 found by liver in the current study. One of the critical issues under 
investigation by several laboratories is the need for this segregation. The three DOs have 
redundant enzymatic activity (i.e. Trp→Kyn metabolism) but they also have non-redundant 
functions such as Ido1-non-enzymatic mediated self-tolerance [90] and Ido2-pro-inflammatory 
mediation of autoimmunity [146]. Clearly in the current work, restraint-stress induces specific 
Ido1, Ido2 and Tdo2 transcripts within astrocytes while decreasing Ido2 and increasing Tdo2 in 
liver. Whether these regulatory profiles result in distinct cellular functions is unknown and 
warrants consideration. Compared to brain, liver greatly over-expresses Ido2-FL, Ido2-v3, Ido2-
v4 and Ido2-v8, consistent with previous reports of abundant hepatic Ido2 protein [128] and 
mRNA [57]. In contrast, Ido2-v1, Ido2-v2, Ido2-v5 and Ido2-v6 expression levels are higher in all 
brain-regions compared to liver (Figure 7 and Figure 8). These data clearly illustrate the 
utilization of alternative-gene processing to produce distinct Ido2 transcript profiles. The ability 
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to fine-tune the Ido2 transcriptome endows the brain and liver with precise regulatory control 
for responding differentially to stressors. 
Hepatic Ido2 expression did not appear to differ significantly between wild-type and 
Ido1KO mice, although Kolodziej [84] found decreased Ido2 expression in inguinal lymph nodes 
of Ido1KO mice. Nevertheless, stress resulted in decreased hepatic Ido2-FL, Ido2-v3 and Ido2-v4 
and striatal Ido2-v1. Again, the functional consequences of these tissue-specific changes on 
behavior remain undetermined.  
Determining the mechanism behind perturbed (diminished) expression of specific Ido2 
transcripts in Ido1KO mice is outside the scope of the current study. Ball et al. hypothesized that, 
since Ido1 and Ido2 are adjacent on mouse (and human) chromosome 8 (Tdo2 is on murine 
chromosome 3), the excision of the 3 exons and intervening introns of the Ido1 gene (Figure 3 
top) may perturb Ido2 expression by disrupting cis-regulatory elements [80]. The Ido1 gene 
(spanning 13 kbp) is located 5' of Ido2 (spanning 22 kbp) with less than 8 kbp's separating the 
two genes on both the mouse and human chromosomes. While both promoters and enhancer 
elements are short DNA sequences (typically 100 bp and 50-1,500 bp, respectively), promoters 
are generally very near the transcription start site (TSS). In contrast, enhancer elements may be 
located far (> 100,000 bp) upstream of the TSS [148]. Thus, enhancers controlling Ido2 
expression could easily reside within the upstream Ido1 gene. Thus far, we are unaware of any 
reports identifying upstream regulatory elements involved in Ido2 expression. However, future 
studies utilizing the commercially available Ido1KO mouse model should consider the 
involvement of both altered Ido2 expression (current work and [80], [100]) and activity[100].  
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Similar to murine Ido2, alternative transcripts for human IDO2 have been described with 
transcripts lacking various exons or initiating at exon 1 or 2 [79], [149]. Human IDO2 transcripts 
containing exon 10 are widely expressed across tissues including liver and brain, but those 
amplified with a forward primer in exon 1a plus reverse primers in either exon 8 or exon 10 are 
limited to placenta and brain [79]. Although not confirmed by qPCR analysis, alternate 
transcripts for human IDO1 and TDO2 have been described [150], [151]. Thus, DO expression 
and regulation in humans is most likely also transcript-, tissue- and cell-specific. 
Characterization of human DO transcript regulation by inflammatory or stress-related signals 
has not been reported.  
Acute stress increases Tdo2-FL expression in brain, astrocytes and liver  
Our data (Figure 9A-C) support previous reports of abundant hepatic expression of Tdo2 
relative to the brain [55], [57] as well as the upregulation of Tdo2 mRNA in liver by restraint-
stress [38], [56] and in brain-slice cultures by glucocorticoids [57]. However, this is the first 
report describing the stress-induced upregulation of hepatic Tdo2-FL and Tdo2-v2 and of all 
three functionally characterized Tdo2 transcripts [55] within whole-brain. However, stress did 
not induce Tdo2 transcripts in selected brain-regions (PFC, Stri, Hippo and Hypo). Similarly, 
Gibney reported no acute stress-induced change in Tdo2-Tot mRNA within the PFC [56], further 
implicating other brain-regions such as the cerebellum or brain stem [37], [55], [85] in the 
central Tdo2 transcriptional response to acute restraint-stress. 
Shimazu first reported increased hepatic Tdo2 activity (in vitro conversion of Trp to Kyn 
by liver homogenate) following peripheral administration of corticosterone, or by stimulation of 
the hypothalamic sympathetic nucleus, both effects seemingly independent of adrenal 
secretions. However, hepatic Tdo2 enzymatic activity was greater when the hypothalamus of 
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animals with intact adrenals were stimulated [58]. Indeed, the addition of the synthetic 
glucocorticoid dexamethasone to primary hepatocytes increases Tdo2 activity [59], [60] and 
mRNA levels [61], [62], [152]. Acute stress also increases hepatic Tdo2 activity [38], [56], [117], 
[135], an effect either reportedly requiring [135] or only partly moderated by adrenal secretions 
[38], [117]. Collectively, these data suggest hepatic Tdo2 activity is increased in a 
glucocorticoid-dependent (stress, corticosterone-induced) and glucocorticoid-independent 
(direct hypothalamic stimulation) manner.  
Whether glucocorticoids directly mediate the upregulation of all three Tdo2 transcripts 
in the brain is unlikely since dexamethasone only upregulated Tdo2-FL in brain-slice cultures 
[57]. Thus, Tdo2-FL induction likely represents the adrenal-dependent transcript in the 
aforementioned studies, whereas Tdo2-v1 and Tdo2-v2 represent the adrenal/glucocorticoid-
independent transcripts. Again, it appears that tissues utilize different DO transcripts to fine-
tune responses to specific physiologic inputs. Defining the Tdo2 transcriptome within specific 
hepatic cell-types is needed to completely understand Tdo2 (and Ido) regulation in response to 
stress.  
Following acute stress, only the glucocorticoid-responsive Tdo2-FL transcript was 
induced within astrocytes. Curiously, the stress-induced increase in Tdo2-FL was preserved in 
astrocytes of Ido1KO mice but not within whole-brain homogenate of Ido1KO mice (Figure 9A). 
Thus, although genetic deletion of Ido1 blocks stress-induced increases of astrocyte Ido2-v3 
(Figure 7B), astrocyte Tdo2-FL expression is still increased by stress in Ido1KO mice (Figure 9A). 
Hence, in astrocytes, the induction of Ido2 is Ido1-dependent, but the induction of Tdo2 is Ido1-
independent. Tdo2 (unknown transcript) is present primarily in neurons and astrocytes [32]. 
The stress-induced increase in Tdo2-v1 and Tdo2-v2 in whole brain is not seen in astrocytes (or 
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microglia). Presumably, this induction is occurring within neurons and surprising requires Ido1 
(Figure 9). Elevated Tdo2 in neurons and astrocytes, along with elevated KynA, is a hallmark of 
schizophrenia [153], [154]. Stress-induced Tdo2 may provide the comorbidity link between 
stress and schizophrenic development and psychosis [114], [155]. 
Downstream Kynurenine Pathway genes and their regulation by stress 
The enzymatic machinery downstream of the DOs define the cellular-specificity of Kyn 
metabolism into neuroactive kynurenines [29], [32]. Astrocytes expressed significantly more 
Kat2 and less Kynu, Kmo and Haao than microglia (Figure 10A-D). Thus, downstream of the DOs, 
the relative expression levels of Kynurenine Pathway enzymes within astrocytes and microglia 
support current dogma which holds that astrocytes predominately produce KynA [32], [47], 
[137], [138], [156] and microglia produce 3-HK and QuinA [32], [42], [51]. Although there are 3 
well-characterized Kat enzymes, Kat2 is believed to account for the majority of KynA production 
in the mammalian brain [157]. Whether Kat1, Kat2 or Kat3 or their mRNA isoforms are 
differentially regulated in the brain or liver in response to stress is not known and outside the 
scope of the current project.  
Downstream Kyn Pathway enzymes are spatially and temporally regulated in the brain 
by inflammation [158] and acute stress [119]. Following acute stress, we found minor changes 
in the expression of these enzymes, such as the increase in astrocyte and microglia KMO. 
Nonetheless, the DOs are considered rate-limiting and DO expression was increased by acute 
stress in astrocytes (Figures 6-8). Both acute and chronic stress increase brain KynA [37], [125] 
despite unchanging Kat2 expression (Figure 10). These findings suggest that the increase in 
KynA is controlled by elevated astrocyte DO expression without a necessary increase in Kat2. In 
contrast to the mild inductions by stress, acute LPS-induced inflammatory responses cause 2 to 
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5 fold increases in KMO expression (dependent on brain region) without induction of Haao or 
Kynu in the mouse brain and small changes in Kat2 expression [158]. These inflammatory 
responses suggest more robust changes in microglial downstream enzymes during 
neuroinflammation compared to stress.  
The relevance of these findings to human well-being remains conjectural. The 
Kynurenine Pathway is implicated in mediating symptoms of depression induced by chronic 
stress and inflammation [109]. Increased plasma Kyn and cerebral spinal fluid levels of Kyn and 
QuinA are associated with depression symptomology in patients treated with IFNα [159]. In 
adolescents, the peripheral Kyn:Trp ratio correlates with anhedonia scores [160] and increased 
suicidality [161]. These findings have been largely attributed to altered IDO1 activity [32] with 
little known regarding the role of IDO2. In contrast, evidence is building for TDO2 involvement 
in human mental health.  
White-matter astrocyte TDO2 immune staining was increased in post mortem frontal 
cortex and anterior cingulate samples of Schizophrenic patients compared to controls [153], 
[162]. Schizophrenic patients have elevated salivary [48], cerebrospinal fluid [163] and frontal 
cortex levels of KynA [163]. Tdo2 mRNA expression in frontal cortex [162] and anterior 
cingulate [153] are greater post mortem in Schizophrenic patients than controls. One hallmark 
of Schizophrenia is the reduced ability of a ‘prepulse’ (or weak cue) to inhibit the natural startle 
response to a subsequent stronger stimulus [164]. Prepulse inhibition is also disrupted by 
increased brain KynA following peripheral administration of Kyn to rodents [165]. Within the 
brain, KynA reduces neurotransmitter activity by antagonizing α7nACh [46] and NMDA 
receptors [42]. Acute stress increases urinary [166] and salivary [48] KynA levels in healthy 
volunteers. Acute stress also increases salivary KynA in Schizophrenic patients and greater KynA 
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levels correlated with greater disease severity [48]. However, we are unaware of studies 
quantifying stress effects on central levels of KynA in humans. Nonetheless, mitigating stress 
[48], [155] and targeting astrocyte DOs and/or KATs are proposed as a therapeutic approaches 
for treating Schizophrenia [109], [112], [154]. While astrocyte Tdo2 is stress-sensitive in rodents 
and implicated in mediating increased central KynA in patients and rodent models of 
Schizophrenia, the expression of alternative DO transcript in humans following stress and in the 
pathogenesis of Schizophrenia remain totally un-defined. 
Conclusions 
Although several studies have implicated the Kynurenine Pathway in stress-induced 
depression-like behavior, the cellular-origin and transcript-specificity of the DOs remained 
undefined. Herein, we report that all three DOs were upregulated by stress in a cell- and 
transcript-specific manner. Specifically, Ido1-v1, Ido2-v3 and Tdo2-FL were all increased in 
astrocytes. In contrast, brain Tdo2-v1 and Tdo2-v2 were upregulated by stress, a response that 
is independent of astrocyte or microglial expression. When only investigating whole-brain or 
brain-regions these subtle but critical changes are easily overlooked. Remarkably, stress did not 
increase several DO transcripts in brain of Ido1KO mice, suggesting an Ido1 requirement for their 
induction. Thus, our data highlight a significant perturbation of Ido2 and Tdo2 regulation within 
the brain of Ido1KO mice. The specific role for astrocytes in acute stress is supported by reports 
of stress-induced increases in central kynurenic acid (KynA) [37], [39], [125], the major 
downstream Kynurenine Pathway product produced by astrocytes [44], [137], [138]. Future 
studies examining the effect of stress on the Kynurenine Pathway should consider the role of all 
three DOs and examine cell-specific changes. Undoubtedly, a single qPCR assay will frequently 
miss cell-specific changes in DO expression.   
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CHAPTER 3: Glia- and tissue-specific changes in the Kynurenine Pathway after 
treatment of mice with lipopolysaccharide and dexamethasone 2 
3.1 Abstract 
 Behavioral symptoms associated with mood disorders have been intimately linked with 
immunological and psychological stress. Induction of immune and stress pathways is 
accompanied by increased tryptophan entry into the Kynurenine Pathway as governed by the 
rate-limiting enzymes indoleamine/tryptophan 2,3-dioxygenases (DOs: Ido1, Ido2, Tdo2). 
Indeed, DO expression is associated with inflammation- and stress-related depression 
symptoms. Here we examined central (whole brain, astrocyte and microglia) and peripheral 
(lung, liver and spleen) DO expression in C57BL/6J mice treated intraperitoneally with 
lipopolysaccharide (LPS), dexamethasone (DEX) or LPS+DEX to model the response of 
Kynurenine Pathway enzymes to inflammation and stress. LPS-induced expression of 
interferon-(Ifn)γ and tumor necrosis factor (Tnf)α was attenuated by DEX, confirming 
inflammatory and anti-inflammatory responses to LPS and DEX, respectively. Increased 
kynurenine levels following LPS and DEX administration verified increased Kynurenine Pathway 
activity. The expression of multiple isoforms for each DO were quantified. LPS increased Ido1-FL 
expression in the mouse brain (~1,000-fold), a response paralleled by increased Ido1-FL 
expression by both astrocytes and microglia. Central Ido1-FL expression was not changed by 
DEX; however, LPS-induced Ido1-FL was decreased by DEX in peripheral tissues. In contrast, DEX 
increased Ido1-v1 expression by astrocytes and microglia, but not by peripheral tissues. In 
2 Edited from original submitted manuscript with headings, figures, and tables renumbered:  
Dostal CR, Gamsby NS, Lawson MA, MCCusker RH. Glia- and tissue-specific changes in the 




comparison to Ido1, brain Ido2 was minimally induced by LPS or DEX. Uniquely, Ido2-v6 was 
LPS- and DEX-inducible only in astrocytes suggesting a unique role for astrocytes in the DO 
response to inflammation and stress. Three Tdo2 isoforms were quantified. DEX increased 
Tdo2-FL expression in brain and astrocytes (not microglia) while LPS failed to induce central 
Tdo2 expression. However, peripheral Tdo2 isoforms were upregulated by LPS and DEX with 
isoform- and tissue-specificity. In summary, expression of specific DO isoforms is increased by 
both LPS and DEX, but LPS-dependent Ido1 and Ido2 induction are attenuated by DEX only in 
the periphery. These findings demonstrate a plausible interaction between immune activation 
and glucocorticoids associated with depression. 
3.2 Introduction 
The brain and immune system have a sophisticated bidirectional relationship that not 
only provides protection for the brain, but also affords a mechanism whereby pro-inflammatory 
cytokines influence mood and behavior. Under most conditions, this action allows appropriate 
immune responses to physiological stressors. However, when inappropriate responses occur, 
major psychiatric sequelae may emerge [29]. Similar to immune-related psychiatric changes, 
the hypothalamic pituitary adrenal (HPA) axis response occurring during immune activation and 
following psychological stress is intimately related to mental wellbeing [29], [167]. Depression is 
a prime example. Major depression, the most common psychiatric disorder in the United 
States, presents more often as a co-morbidity to other illnesses rather than alone [107], [108]. 
In fact, major depression is frequently associated with elevated corticosteroid levels resulting 
from dysfunction of the HPA axis [168]–[170] and elevated levels of pro-inflammatory cytokines 
[171]–[173]. Further defining the relationship between the brain and the immune system 
 
45 
should aid in the development of new treatments for depression and other psychiatric 
disorders [174].  
Physiological challenges such as infection, cancer, heart disease or perceived 
psychological stress activate the immune system and increase HPA axis activity [175]. In turn, 
resultant pro-inflammatory cytokine and adrenocortical secretions induce the Kynurenine 
Pathway [54]. Evidence continues to accumulate implicating increased levels of tryptophan 
metabolites (i.e. kynurenines) in precipitating or mediating depression symptomology [32], 
[109], [111], [161], [176]–[178]. Tryptophan (Trp) entry into the Kynurenine (Kyn) Pathway is 
governed by the indoleamine and tryptophan 2,3-dioxygenases (DOs: Ido1, Ido2, Tdo2). It is 
currently accepted that Ido1 and Ido2 are upregulated by pro-inflammatory cytokines, whereas 
Tdo2 is controlled by corticosteroids [54]. Although inflammatory cytokines and stress-induced 
corticosteroids may individually contribute to disease morbidity and mortality via DO 
upregulation [109], [179], [180], the interacting effects of inflammatory mediators and 
glucocorticoids on DO expression remain poorly defined.  
Increased DO expression results in increased Trp → Kyn metabolism and the subsequent 
production of downstream kynurenines (Kyn's). An underappreciated aspect of this field is the 
cell-specific generation of unique Kyn's with opposing effects [32]. In the brain for example, 
quinolinic acid (QuinA) generated predominantly by microglia is a glutamate receptor (N-
methyl-D-aspartate, NMDA-R) agonist while kynurenine acid (KynA) generated by neurons and 
astrocytes is a NMDA-R antagonist [54]. In addition to their neuromodulatory functions, Kyn's 
are also immunomodulatory largely by the ability of Kyn and KynA to bind and activate the aryl 
hydrocarbon receptor and suppress the immune response [31]. Thus, an imbalance in Kyn's is 
implicated in various illnesses including neurodegenerative disorders [181], [182], autoimmune 
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diseases [101], [183]–[185], cancer [95], [132], [179] and psychiatric conditions such as 
schizophrenia [48], [112], [186] and depression [111], [159], [176], [178], [187]. 
Data generated with animal models demonstrate that inflammation- or stress-induced 
depression-like behaviors and cognitive deficits are DO-dependent [33], [35], [56], [67], [68], 
[125]. Both inflammation and stress increase DO activity in the central nervous system and 
peripheral tissues. Thus, we probed the interacting effects of LPS (an immune system activator 
used to model an acute inflammatory response) and DEX (a glucocorticoid receptor agonist 
used to model an acute stress response) on DO mRNA expression in both central (brain, 
astrocytes and microglia) and peripheral (liver, lung and spleen) samples. 
3.3 Methods 
Animals 
Male C57BL/6J mice (Bar Harbor, ME, USA) kept on a reversed 12 h light-dark cycle with 
ad libitum access to food and water were individually housed 3 weeks prior to experiments. 
Mice were handled for 5 consecutive days prior to treatment and were 15 weeks of age at the 
time of treatment. All animal procedures were approved by the Institutional Animal Care and 
Use Committee and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Research Council). 
Intraperitoneal (i.p.) treatments 
Mice were injected just prior to onset of the dark cycle with either saline (Control) or 
saline containing lipopolysaccharide (LPS; 0.83 mg/kg body weight final dosage, serotype 
0127:B8, Sigma), dexamethasone (DEX; 10 mg/kg body weight final dosage, 11695-4013-1, 
Henry Shein) or a single injection to deliver LPS+DEX. Mice were euthanized by CO2 
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asphyxiation 5 h after treatment. To confirm treatment effectiveness associated with this short 
treatment interval, changes in body weight and food intake were quantified. Statistical analysis 
indicated that both LPS (p<0.05) and DEX (p<0.05) reduced body weight (∆ body weight: 
Control 0.2±0.1 g, LPS -1.3±0.1 g, DEX -0.2±0.1 g, LPS+DEX -2.2±0.2 g), but only LPS (p<0.05) 
reduced 5 h food intake (Control 1.3±0.1 g, LPS 0.2±0.2 g, DEX 1.6±0.2 g, LPS+DEX 0.1±0.0 g). 
Glia enrichment (cohort 1) 
After a 5 h treatment and following intracardial perfusion with 30 ml of ice-cold PBS 
containing 2 mM EDTA, brains were removed and gently homogenized. Whole brain 
homogenates were sampled prior to the enrichment of astrocytes and microglia by magnet-
assisted cell separation (Miltenyi Biotec Inc.) as recently described [86]. Brain homogenate, 
microglia and astrocyte samples were suspended in TRIzol and stored at -80 °C until processed 
for assessment of gene expression.  
Tissue collection (cohort 2) 
After a 5 h after treatment, blood was collected from the inferior vena cava immediately 
prior to intracardial perfusion with ice-cold PBS. After perfusion, brain and peripheral tissues 
(liver, lung, spleen) were harvested, immediately frozen in liquid N2 and then stored at -80 °C. 
Brain and plasma were processed as previously reported for Kyn content [86]. Peripheral 
tissues from this cohort of mice were processed for gene expression. 
Gene expression by qPCR 
Methods for RNA extraction, reverse-transcription and analysis of quantitative 
polymerase chain reaction (qPCR) data were recently described in detail [86]. Within each 
tissue or cell-type, the expression of each test gene was normalized to Gapdh using the 2-ΔΔCt 
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method, Ct = cycle threshold [131]. Gene expression in the Control group was set to 1.0 and 
other treatment groups are expressed as fold expression relative to Control. DO gene structure 
and known mRNA transcripts were previously described [86]. PCR probe-based assays were 
purchased from IDT (Coralville, Iowa) and custom assays were designed using the IDT 
PrimerQuest® Design Tool. Because of low expression, some transcripts are 'not detectable' in 
all samples (i.e. Ct values 'undetermined') thus preventing calculation of relative gene 
expression; for analysis, a Ct value of 40.0 is assigned when this occurs. 
HPLC 
To measure Kyn, brain and plasma samples were analyzed by high pressure liquid 
chromatography (HPLC) with electrochemical detection using methods recently described in 
detail [86].  
Statistics 
Data are presented as mean ± SEM representing 4-6 mice per treatment group. Two-
way ANOVA was performed for all data. Significance was set at p ≤ 0.05. In the absence of a 
statistical interaction between treatments, significant main effects of LPS or DEX are annotated 
with * or φ, respectively. In the presence of a significant statistical interaction between LPS and 
DEX, data are annotated with δ to represent significant effects by post hoc analysis using the 
Holm-Šídák method. Graphic presentation and statistical analysis were completed using 




DEX is anti-inflammatory in peripheral tissues when co-administered with LPS 
FK506 binding protein 5 (Fkbp5) expression was assessed to confirm glucocorticoid-
receptor mediated responses [133], [134]. Fkbp5 is well expressed by all 4 tissues (Figure 11, Ct 
of Controls (Ctrl/-) presented above each graph, for each tissue). In brain, Fkbp5 expression was 
increased 3.4-fold by LPS and 5.9-fold by DEX relative to Controls. The effect of LPS indicates 
inflammation-dependent induction of the HPA axis [188]. DEX also increased Fkbp5 expression 
in liver, lung and spleen relative to Control. LPS caused a smaller increase in Fkbp5 expression in 
liver and lung when compared to DEX, but LPS did not increase Fkbp5 in spleen. Co-treatment 
of LPS+DEX did not result in greater Fkbp5 within these peripheral tissues compared to either 
treatment alone, suggesting saturation of the peripheral glucocorticoid response by DEX alone. 
Ifnγ and Tnfα expression were quantified to determine relative ability of LPS and DEX to 
modulate an inflammatory response. Ifnγ expression was not detected in brains (Figure 11B, 
see Control Ct value) with the highest expression measured in spleen. LPS did not induce Ifnγ 
expression in the brain, but increased Ifnγ expression in liver, lung and spleen (Figure 11B). The 
increase in Ifnγ expression caused by LPS was abrogated by co-administration of DEX in all three 
peripheral tissues. Tnfα expression in brain, liver, lung and spleen was elevated by LPS (Figure 
11C). LPS-induced Tnfα was significantly attenuated by DEX co-treatment for all three 
peripheral tissues, but not in the brain. 
Together these data indicate HPA axis activation by LPS with a smaller glucocorticoid-
like effect than DEX administration. In contrast, LPS induces an inflammatory response that is 
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antagonized by DEX, but only in the periphery. These data provide strong evidence of treatment 
efficacy. 
 
Figure 11. DEX is anti-inflammatory in peripheral tissues when co-administered with LPS. 
Perfused brain, liver, lung and spleen tissues were obtained from mice 5 h after i.p. treatment 
with saline (Control), LPS, DEX, or LPS+DEX to assess HPA activity by quantifying (A) Fkbp51 
expression and to assess an inflammatory response by quantifying (B) Ifnγ and (C) Tnfα 
expression. * p < 0.05 main effect of LPS. φ p < 0.05 main effect of DEX. δ p < 0.05 post hoc mean 
separation (brackets) in the presence of a significant LPS x DEX interaction. 
Kyn levels increase in brain following LPS and in plasma following DEX 
Kyn was quantified to confirm Kynurenine Pathway activation. Plasma Kyn (Figure 12A) 
was elevated ~50% following DEX administration. LPS did not increase plasma Kyn, but 
prevented the increase triggered by DEX. In contrast, brain Kyn (Figure 12B) was doubled by 
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LPS. DEX did not change brain Kyn but prevented the increase produced by LPS. These data 
strongly illustrate independent increases in Kynurenine Pathway activity in the periphery and 
brain following DEX and LPS treatments, respectively. 
 
Figure 12. Kyn levels increase in brain following LPS and in plasma following DEX. (A) Plasma 
and (B) brains were obtained from mice 5 h after i.p. treatment with saline (Control), LPS, DEX, or 
LPS+DEX to assess Kyn levels by high pressure liquid chromatography. * p < 0.05 main effect of 
LPS. φ p < 0.05 main effect of DEX. δ p < 0.05 post hoc mean separation in the presence of a 
significant LPS x DEX interaction. 
LPS and DEX differentially regulate Ido1 expression in brain, glia and peripheral 
tissues 
Expression of the reference full-length Ido1 transcript (Ido1-FL: NM_008324.2), two 
other protein coding mRNA isoforms (Ido1-v1: NM_001293690.1 and Ido1-v2: 
XM_006509018.1) and their combined expression (Ido1-Tot) were quantified. 
Ido1-FL is poorly expressed in naïve brain, astrocytes and microglia (Figure 13A, see 
Control Ct values). Even so, Ido1-FL is strongly induced 5 h after LPS treatment. DEX did not 
alter Ido1-FL expression in these samples, either alone or in combination with LPS. These data 
strongly suggest that a large portion of the brain's response to LPS reflects Ido1-FL induction 
within both astrocytes and microglia. Although several publications describe Ido1 induction by 
microglia [189]–[191], our data clearly show that astrocytes respond robustly to LPS 
administration (numerically a greater fold-increase than microglia). In the periphery, Ido1-FL is 
expressed best by lungs, followed by spleens and livers from naïve mice (see Control Ct values). 
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LPS increased Ido1-FL expression in liver, lung and spleen, but DEX alone was ineffective. LPS-
induced Ido1-FL expression was significantly reduced by DEX co-administration in all three 
peripheral tissues. Thus, Ido1-FL is responsive to inflammatory stimuli across many tissues. 
Interestingly, LPS-induced Ido1-FL is abrogated by DEX only in peripheral tissues. 
Ido1-v1 is the only Ido1 isoform appreciably expressed in naïve mouse brains (Figure 
13B, Control Ct = 33.1). Ido1-v1 expression in whole brain was unaltered by LPS or DEX. 
However, LPS increased Ido1-v1 expression in astrocytes, but not microglia. Ido1-v1 expression 
by astrocytes, and less so by microglia, was DEX-inducible compared to Controls (Figure 13B). 
Elevated Ido1-v1 expression by glia without noteworthy changes in brain tissue might seem 
inconsistent at first glance. However, Ido1-v1 expression in Control astrocytes and microglia is 
lower than brain (a brain Ct of 33.1 represents ~13-fold greater expression compared to the 
astrocyte Ct of 36.8 and ~42-fold greater expression compared to the microglia Ct of 38.5). 
These data indicate that most Ido1-v1 in brain is not derived from these glia, but from a LPS and 
DEX insensitive cell-type(s). Thus, the increase in astrocyte and microglial Ido1-v1 expression 
was insufficient to impact brain expression because of their lower expression levels. In 
peripheral tissues, Ido1-v1 was not elevated by DEX and LPS only increased Ido1-v1 in the lung 
where its induction was attenuated by DEX co-treatment. LPS also slightly decreased Ido1-v1 
expression in the spleen independently of DEX. Thus, DEX increased Ido1-v1 expression within 
astrocytes and microglia, but not in whole brain or any peripheral tissue examined. This 
indicates that detecting physiologically relevant changes in Ido1-v1 may require examination of 
each tissues individual component cell-types. 
Ido1-v2 expression (Figure 13C) was essentially absent in brain, astrocytes, microglia, 
liver or spleen. Only in lung was Ido1-v2 detected. Ido1-v2 was strongly induced by LPS in lung 
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where its expression was attenuated by DEX. Thus, among the tissues tested, the lung is unique 
in its ability to express Ido1-v2. 
Ido1-Tot expression (Figure 13D) detects all three Ido1 isoforms, but its expression in 
Control brains reflects the expression of Ido1-v1 (Figure 13B & D, Control Ct's both ≈ 33). In 
brain, LPS increases Ido1-Tot expression ~10-fold, a marked attenuation relative to the ~1,000-
fold increase in Ido1-FL. Thus, the fold-change in Ido1-FL overestimates the change in total 
brain Ido1 expression. Moreover, the ability of DEX to increase Ido1 expression by astrocytes 
and microglia is overlooked when quantifying Ido1-Tot since only Ido1-v1 is affected by DEX. In 
liver, Ido1-Tot expression mimics Ido1-FL as only this isoform is induced by LPS and inhibited by 
DEX. In contrast, within the lung there are no differentially expressed Ido1 isoforms; therefore, 
Ido1-Tot expression reflects changes in any particular isoform or the sum of all 3 isoforms. In 
the spleen, the Ido1 isoforms are differentially responsive to treatment; changes in Ido1-Tot 
reflect LPS-induced Ido1-FL as tempered by reduced Ido1-v1. The differential regulation of 
splenic Ido1-FL and Ido1-v1 likely reflect increases of Ido1-FL expression in one cell-type and 
decreases in Ido1-v1 expression by another, but exploring this possibility was outside the scope 
of the current research. 
Together (summarized in Table 2), these data demonstrate transcript-, tissue- and 
cellular-specificity of Ido1 regulation using models of inflammation and stress. Although DEX 
has a net ability to temper Ido1 induction in the periphery, the overall effect within the brain is 
unchanged Ido1-FL and increased Ido1-v1 expression. These data also demonstrate that 
astrocytes and microglia are major expressers of LPS-induced Ido1-FL but not major sources of 
Ido1-v1 in the brain. Remarkably, Ido1 expression is induced in these glia by either LPS or DEX 
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administration in an isoform-specific manner. The three murine isoforms are differentially 
regulated in vivo and thus Ido1-Tot does not necessarily reflect their individual changes. 
 
Figure 13. LPS and DEX differentially regulate Ido1 expression in brain, glia and peripheral tissues. Brain, 
astrocytes, microglia, liver, lung and spleen were obtained from mice 5 h after i.p. treatment with saline 
(Control), LPS, DEX or LPS+DEX to assess the relative changes in the mRNA expression of (A) Ido1-FL, (B) 
Ido1-v1, (C) Ido1-v2 and (D) Ido1-Tot. * p < 0.05 main effect of LPS. φ p < 0.05 main effect of DEX. δ p < 
0.05 post hoc mean separation in the presence of a significant LPS x DEX interaction. 
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LPS and DEX regulate Ido2 transcripts in a manner distinct from Ido1 
Since murine Ido2 demonstrates transcript-specific regulation [86], [126], [190], eight 
variant (v) isoforms (Ido2-v1 (XM_006509048), Ido2-v2 (XM_0011242130), Ido2-v3 (∆4, [100]), 
Ido2-v4 (XM_006509046), Ido2-v5 (XM_006509047), Ido2-v6 (EU440733.1), Ido2-v7 
(AK082385.1), Ido2-v8 (XM_01124131)), the reference transcript Ido2-FL (NM_145949.2) and 
their combined expression (Ido2-Tot) were quantified to define cell- and tissue-specific 
expression profiles. 
Ido2-v1 expression is greater in brain compared to astrocytes, microglia and peripheral 
tissues (Figure 14A, see Control Ct values). Ido2-v1 expression by brain is unchanged following 
LPS or DEX treatments. However, LPS increases Ido2-v1 expression 17-fold in astrocytes and 5-
fold in microglia. The LPS induction of glial Ido2-v1 is not adequate to change whole brain 
expression because of low basal glial expression levels relative to brain. These data indicate 
that astrocytes and microglia are not major sources of brain Ido2-v1. An LPS/DEX-insensitive 
cell-type(s) must be the primary source of brain Ido2-v1 (mimicking Ido1-v1). In the periphery, 
LPS increases expression of Ido2-v1 in liver, lung and spleen. DEX alone does not change hepatic 
Ido2-v1 expression, abrogated the LPS effect in lung, but synergized with LPS to further elevate 
Ido2-v1 in spleen. Thus, Ido2-v1 expression is LPS and DEX responsive but in a cell-type and 
tissue-specific manner. 
Ido2-v2 expression is similar in brain, astrocytes, microglia and liver, all with greater 
expression than lung or spleen (Figure 14B, see Control Ct values). These data indicate these glia 
are a major source of central Ido2-v2. Ido2-v2 expression in brain was not changed by either 
LPS or DEX alone but slightly elevated by LPS+DEX. This induction is not evident within 
astrocytes or microglia. By contrast, Ido2-v2 expression is diminished in liver by LPS, unchanged 
 
56 
in lung, but increased in spleen by LPS and DEX. Thus, Ido2-v2 expression is relatively stable in 
brain and glia, but regulation in the periphery is tissue-specific. 
Ido2-v3 is better expressed by brain when compared to astrocytes and microglia, but in 
the periphery its expression is greatest in the liver followed by spleen and lowest in lung (Figure 
14C, Ct values). These data illustrate that neither astrocytes nor microglia are the major source 
of central Ido2-v3. Ido2-v3 expression is slightly increased by LPS in brain and by LPS+DEX in 
microglia, but not astrocytes. LPS has opposing effects on Ido2-v3 expression in liver and 
spleen, decreasing hepatic expression and increasing splenic expression (somewhat mimicking 
Ido2-v2). LPS induces Ido2-v3 expression in the lung, an effect completely blocked by DEX. Thus, 
Ido2-v3 expression is relatively stable in brain and astrocytes, albeit inducible in microglia, but 
LPS and DEX responsiveness in the periphery occurs again in a tissue-specific manner. 
Ido2-v6 expression is greatest in the brain, but poorly expressed in astrocytes, microglia, 
liver, lung and spleen (Figure 14D, Ct values). These data indicate that most of the Ido2-v6 in 
brain is not within these glia. Ido2-v6 expression in brain and microglia is unchanged by 
treatments, whereas astrocyte Ido2-v6 expression is increased by LPS and DEX. LPS also 
increases Ido2-v6 expression in liver, lung and spleen. DEX co-treatment abrogated LPS-induced 
expression in liver and lung, but by itself increased Ido2-v6 expression in spleen. Thus Ido2-v6 
expression is relatively stable in brain and microglia, albeit inducible in astrocytes, but LPS and 
DEX responsiveness in the periphery occurs in a tissue-specific manner. 
Ido2-v5 expression was only detected in brain, where it was increased by LPS (Figure 
14E). Ido2-FL (the major hepatic isoform), Ido2-v4, Ido2-v7 and Ido2-v8 were only detected in 
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liver, where their expression levels were all decreased by LPS independently of DEX (Figure 14F-
I).  
Ido2-Tot expression (Figure 14J) represents the integrated effects of LPS or DEX on the 
multiple Ido2 mRNA isoforms. Alone, however, Ido2-Tot expression does not adequately define 
the elaborate isoform-specific regulation of Ido2 by LPS and DEX. For example, Ido2-Tot does 
not reflect the ability of LPS to induce Ido2-v1 and Ido2-v6 in astrocytes or Ido2-v1 in liver. Like 
Ido1, Ido2 isoform expression is likely cell-type specific within each tissue and work similar to 
our comparison of brain vs. astrocyte vs. microglia is needed to adequately define Ido2 
regulation. 
Therefore (summarized in Table 2), Ido2 exhibits regulation by LPS and DEX. These data 
suggest that astrocytes and microglia are not the major source of Ido2 in the brain, even after 





Figure 14. LPS and DEX regulate Ido2 transcripts in a manner distinct from Ido1. Brain, astrocytes, microglia, liver, 
lung and spleen were obtained from mice 5 h after i.p. treatment with saline (Control), LPS, DEX or LPS+DEX to 
assess the relative changes in the mRNA expression of (A) Ido2-v1, (B) Ido2-v2, (C) Ido2-v3, (D) Ido2-v6, (E) Ido2-v5, 
(F) Ido2-FL, (G) Ido2-v4, (H) Ido2-v7, (I) Ido2-v8 and (J) Ido2-Tot. * p < 0.05 main effect of LPS. φ p < 0.05 main effect 
of DEX. δ p < 0.05 post hoc mean separation in the presence of a significant LPS x DEX interaction. 
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DEX upregulates Tdo2-FL while inflammation regulates Tdo2-v1 and Tdo2-v2 
Tdo2 expression is widely viewed as glucocorticoid-inducible. Thus, we quantified the 
expression of the three known Tdo2 isoforms: the reference isoform Tdo2-FL (NM_019911.2), 
Tdo2-v1 (AB476989.1), Tdo2-v2 (AB476990.1) and their combined expression (Tdo2-Tot) after 
i.p. treatment with LPS and DEX.  
Tdo2-FL is well expressed by brain and astrocytes, but less so by microglia. However, 
expression is highest in liver and lowest in spleen (Figure 15A, Ct values). Tdo2-FL expression 
increases in brain and astrocytes following DEX administration, but not in microglia. Tdo2-FL 
also increases after DEX administration in all three peripheral tissues. LPS only induces Tdo2-FL 
expression in liver. Thus, as expected from previous work, Tdo2-FL expression is glucocorticoid-
dependent. The ability of LPS to increase liver Tdo2-FL may reflect HPA axis activation and 
subsequent glucocorticoid release and action. 
Tdo2-v1 and Tdo2-v2 expression are similarly expressed and regulated. Tdo2-v1/v2 are 
best expressed by the liver, next highest in astrocytes, then slightly lower in microglia, lung, 
brain and spleen (Figure 15B-C, Ct values). Thus, astrocytes and microglia are major sources of 
central Tdo2-v1/v2. Their expression is unchanged by LPS and DEX in brain, astrocyte and 
microglia, but regulated in a tissue-specific manner within the periphery. DEX increased Tdo2-
v1/v2 expression in liver and lung, but not spleen. In contrast, LPS increases Tdo2-v1/v2 
expression in liver and spleen, but not lung. Interestingly, LPS-inducible splenic Tdo2-v1/v2 
expression was blocked by DEX. Thus, Tdo2-v1/v2 expression by liver and lung is glucocorticoid-
inducible, but their expression is LPS sensitive in liver and spleen. 
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Tdo2-Tot (Figure 15D) expression represents a composite of the three Tdo2 isoforms. In 
brain, Tdo2-Tot is not changed by LPS or DEX. When using this assay, the stimulatory effect of 
DEX on brain Tdo2-FL is completely missed because Tdo2-Tot also detects the two unresponsive 
isoforms. With astrocytes and microglia, Tdo2-Tot expression reflects Tdo2-FL induction by 
astrocytes and unchanged isoform expression in microglia. In liver, all Tdo2 isoforms are 
induced by both LPS and DEX; this is reflected by Tdo2-Tot expression. Similarly, in lung all Tdo2 
isoforms are DEX inducible as is Tdo2-Tot. However, in spleen Tdo2-Tot expression is 
problematic. Splenic Tdo2-Tot is not significantly changed by LPS or DEX, completely 
overlooking the ability of DEX to induce Tdo2-FL and LPS to induce Tdo2-v1/v2. The differential 
expression of Tdo2 isoforms is likely a cell-type specific phenomenon and overlooked when 




Figure 15. DEX upregulates Tdo2-FL while inflammation regulates Tdo2-v1 and Tdo2-v2. Brain, 
astrocytes, microglia, liver, lung and spleen were obtained from mice 5 h after i.p. treatment 
with saline (Control), LPS, DEX or LPS+DEX to assess the relative changes in the mRNA expression 
of (A) Tdo2-FL, (B) Tdo2-v1, (C) Tdo2-v2 and (D) Tdo2-Tot. * p < 0.05 main effect of LPS. φ p < 0.05 
main effect of DEX. δ p < 0.05 post hoc mean separation in the presence of a significant LPS x DEX 
interaction.   
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Table 2. Summary of changes in DO expression. 
 
Downstream Kynurenine Pathway enzyme regulation by LPS, DEX and LPS+DEX 
Kyn production is limited by the DOs, but Kyn is then metabolized into immune- and 
neuro-modulatory kynurenines associated with various pathologies. Kynurenine 
aminotransferase 2 (Kat2) converts Kyn into KynA, whereas kynurenine 3-monooxygenase 
(Kmo), kynureninase (Kynu) and 3-hydroxyanthranilate 3,4-dioxygenase (Haao) function to 
convert Kyn to QuinA. These downstream enzymes are expressed with tissue- and glia-
specificity; we report their regulation by LPS and DEX. 
Kat2 expression is largely unchanged albeit slightly induced in the liver by DEX (Figure 
16A). Kat2 expression is ~10-fold higher (3.5 lower Ct) in astrocytes compared to microglia, 
reflecting the ability of astrocytes to produce KynA in the brain [112]. Kat2 is also highly 
expressed in liver supporting a well-developed ability for hepatic KynA production [192], [193]. 
 brain  astrocyte  microglia  liver  lung  spleen 
 LPS  DEX  LPS  DEX  LPS  DEX  LPS  DEX  LPS  DEX  LPS  DEX 
Ido1-FL ↑↑↑  -  ↑↑↑  -  ↑↑↑  -  ↑  ∙ ↓  ↑↑  ∙ ↓  ↑  ∙ ↓ 
Ido1-v1 -  -  ↑  ↑  -  ↑  ↑  -  ↑  ∙ ↓  ↓  - 
Ido1-v2 ND  ND  ND  ND  ND  ND  ND  ND  ↑↑  ∙ ↓↓  ND  ND 
Ido1-Tot ↑  -  ↑  -  ↑  -  ↑  ∙ ↓  ↑↑ ∙ ↓  ↑  ∙ ↓ 
                        
Ido2-FL ND  ND  ND  ND  ND  ND  ↓  -  ND  ND  ND  ND 
Ido2-v1 -  -  ↑  -  ↑  -  ↑  -  ↑  ∙ ↓  ↑  ∙ ↑ 
Ido2-v2 ↑  ∙ ↑  -  -  -  -  ↓  -  -    ↑  ↑ 
Ido2-v3, ∆4 ↑  -  -  -  ↑  ∙ ↑  ↓  -  ↑  ∙ ↓  ↑   
Ido2-v4 ND  ND  ND  ND  ND  ND  ↓  -  ND  ND  ND  ND 
Ido2-v5 ↑  -  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND 
Ido2-v6 -  -  ↑  ↑  -  -  ↑  ∙ ↓  ↑  ∙ ↓  ↑  ↑ 
Ido2-v7 ND  ND  ND  ND  ND  ND  ↓  -  ND  ND  ND  ND 
Ido2-v8 ND  ND  ND  ND  ND  ND  ↓  -  ND  ND  ND  ND 
Ido2-Tot -  -  -  ↑  -  -  ↓    ↑  ∙ ↓  ↑  ∙ ↑ 
                        
Tdo2-FL -  ↑  -  ↑  -  -  ↑  ↑  -  ↑  -  ↑ 
Tdo2-v1 -  -  -  -  -  -  ↑  ↑  -  ↑  ↑  ∙ ↓ 
Tdo2-v2 -  -  -  -  -  -  ↑  ↑  -  ↑  ↑  ∙ ↓ 
Tdo2-Tot -  -  -  ↑  -  -  ↑  ↑  -  ↑  -  - 
ND = not detected. ∙ Dex by LPS treatment interaction 
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Kmo, Kynu and Haao (Figure 16B-D) expression were not increased in brain or glia, but 
brain Haao is decreased 5 h after LPS treatment. Surprisingly, microglial expression of all three 
enzymes is diminished by LPS and DEX. Haao expression by astrocytes is also diminished by 
DEX. Microglial expression of these three enzymes was greater than that of astrocytes, 
reflecting microglial ability to generate QuinA. Kmo is induced by LPS in lung but unchanged by 
LPS or DEX in spleen. Kmo, Kynu and Haao are best expressed by the liver compared to the 
other 3 tissues; this reflects the well-accepted hepatic ability to generate QuinA and then NAD+ 
from Kyn. In liver, LPS increases Kmo, but both LPS and DEX decrease Kynu and Haao 
expression; since Kmo acts upstream of Kynu its increase is offset by lowered Kynu. Although 
not considered rate-limiting, these changes suggest a slight diminution in Kynurenine Pathway 





Figure 16: Downstream Kynurenine Pathway enzyme regulation by LPS, DEX and LPS+DEX. 
Brain, astrocytes, microglia, liver, lung and spleen were obtained from mice 5 h after i.p. 
treatment with saline (Control), LPS, DEX or LPS+DEX to assess the relative changes in the mRNA 
expression of (A) Kat2, (B) Kmo, (C) Kynu and (D) Haao. * p < 0.05 main effect of LPS. φ p < 0.05 






Immunogenic and psychological stress responses result in DO-dependent changes in 
immunophysiology [100], [101], [194]–[196], behavior [56], [71], [142] and cognition [67], 
[197], [198]. Changes in cytokine levels [171] and HPA axis function [199], [200] also accompany 
psychiatric conditions linked to DO activity [109], [110]. Although inflammatory mediators can 
affect HPA axis function and vice versa [25]–[27], [201], only recently have we began defining 
how inflammation and stress interact to control DO expression. The DOs are regulated with 
remarkable specificity, illustrated by the intricate interactions between inflammatory mediators 
and glucocorticoids on DO expression found ex vivo using organotypic hippocampal slice 
cultures (OHSCs) [57], [126], [190]. We extend those findings by describing interacting effects of 
pro-inflammatory (LPS) and anti-inflammatory (DEX) treatments on Kynurenine Pathway 
activity and DO expression in vivo.  
DEX is anti-inflammatory in peripheral tissues when co-administered with LPS 
Fkbp5 induction was used as an index of glucocorticoid receptor (GR) activation [133], 
[134]. LPS-induced Fkbp5 (Figure 11A) reflects inflammation-induced HPA-axis activation [120], 
[188], [202]. DEX had greater effects on Fkbp5 than LPS reflecting greater GR activation by the 
GR agonist [203], [204]. LPS also induces a pro-inflammatory response [33], [77], [126], [158], 
[202], [205]–[207], confirmed here by increases in both brain and peripheral TNFα expression 
(Figure 11C). DEX acted as an anti-inflammatory agent, blocking Ifnγ and Tnfα induction in 
peripheral tissues (Figure 11B-C). This effect was tissue-specific as DEX did not suppress brain 
Tnfα.  
Together, these data indicate that DEX is active in the brain, but has a stronger anti-
inflammatory action in the periphery. Changes in DO expression will be affected directly by 
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cytokines induced by LPS and by GR activation by DEX, in both the brain and periphery. 
Alternatively, DEX will alter DO expression by limiting the peripheral, but not central, 
inflammatory response.  
Kyn levels increase in brain following LPS and in plasma following DEX 
Changes in Kyn demonstrate functional alterations in Trp metabolism along the 
Kynurenine Pathway. Tdo2 appears to limit, not drive, blood Kyn as Tdo2KO mice have very high 
levels of circulating Kyn [208], [209]. Ido2KO mice have unchanged blood Kyn [100], but Ido1KO 
mice have diminished Kyn levels [85], [86], [95]. Thus, it is dogmatically accepted that elevated 
circulating Kyn is Ido1-dependent. Here, DEX increased plasma Kyn (Figure 12A) without 
changes in peripheral Ido1 expression. However, DEX increased spleen Ido2 as well as liver, lung 
and spleen Tdo2 expression indicating that even transient glucocorticoid release associated 
with HPA axis activation would be sufficient to increase circulating Kyn, albeit the source of Kyn 
production remains undefined. 
Kyn crosses the blood-brain barrier [78], allowing peripherally administered Kyn to 
elevate brain Kyn [67]. Thus, plasma and brain Kyn would expectedly increase together. 
However, DEX increased plasma but not brain Kyn (Figure 12). By contrast, acute stress 
increases both plasma and brain Kyn [36], [37], [86]. The difference is that stress increases 
cytokine expression [86], DEX does not (Figure 11B-C). Thus, in the context of psychological 
stress, elevated brain Kyn could result from inflammation-induced local Kyn production.  
Both plasma [53], [75], [158], [210] and brain [33], [53], [210], [211] Kyn levels are 
elevated when assessed 24 h after LPS administration suggesting coupling of plasma and brain 
Kyn. However, when LPS is administered directly into the brain, Kyn is only increased in brain 
and not plasma, demonstrating that the brain is fully equipped for local Kyn production [212]. 
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Five hours after LPS treatment, brain (Figure 12B, [213]), but not plasma (Figure 12A), Kyn levels 
are elevated. Since plasma Kyn is not increased, an elevation in brain Kyn reflects central Kyn 
production. This action is likely mediated by the striking ability of LPS to increase Ido1 and Ido2 
expression within both astrocytes and microglia. Together, these data demonstrate that DEX 
increases peripheral Kyn levels and LPS-induced inflammatory responses can independently 
increase central Kyn production. 
LPS and DEX differentially regulate Ido1 expression in brain, glia and peripheral 
tissues 
Inflammation and stress induce depression-like behaviors associated with Ido1 
induction; such as helplessness/despair [33], [66]–[72], anhedonia [68], [71], [72] and cognitive 
dysfunction [67], [72]. Importantly, increased brain Ido1-FL [33], [67], [68] and Ido1-Tot [69], 
[71] expression are associated with these depression-like behaviors. Despite the ability of stress 
to enhance LPS-driven depression-like behavior [214], interactions between inflammation- and 
glucocorticoid-dependent Ido1 expression are poorly defined. 
Ido1-FL is poorly expressed in naïve mouse brains, astrocytes and microglia (Figure 13A, 
see Ct values). However, central Ido1-FL is robustly induced in brain by immune activation via 
treatments with complete Freund's adjuvant [215], BCG [35], [142], pI:C [126] and LPS (Figure 
13A, [33], [67], [77], [120], [126], [158], [189], [216], [217]). Notably, our new data demonstrate 
that LPS induces Ido1-FL expression by astrocytes at least as well as in microglia. Current dogma 
suggests that inflammation increases microglial Ido1 with resultant behavioral changes [32], 
[218]. Based on the current findings, astrocyte involvement in inflammation-dependent 
behaviors need re-evaluation [54].  
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Our data clearly reveal that Ido1-v1 is the major isoform expressed in naïve brain [57], 
[86], indicating that Ido1-v1 is the only isoform available to generate Ido1 activity in the brain. 
Herein we demonstrate that Ido1-v1 is induced by LPS and DEX within astrocytes (Figure 13B). 
Also, Ido1-v1 (not Ido1-FL) was induced by stress within astrocytes, not microglia [86], 
indicating that Ido1 expression by astrocytes is glucocorticoid-sensitive. Reports also 
demonstrate that inflammation [53] and stress [37], [125], [219] increase brain KynA, 
consistent with functional changes in the brain mediated by astrocytes. 
Ido1 isoforms are differentially regulated in peripheral tissues (summarized in Table 2). 
Ido1-FL is increased by LPS and diminished by DEX in liver, lung and spleen, demonstrating a 
prototypical inflammatory/anti-inflammatory GR-mediated response. Conversely, Ido1-v1 is 
diminished by LPS in spleen and unresponsive to DEX. Together, this suggests some peripheral 
cell-types respond differently to inflammation and stress, but defining the significance of these 
unique changes in Ido1 regulation requires additional work. Clearly, the intricacies of Ido1 
regulation may be overlooked with a single assay. Likely cells from each tissue respond with 
distinctive DO isoform profiles. Differences in Ido1 regulation will result in cell-specific changes 
in physiology (by generating intracellular kynurenines) and/or changes in the physiology of 
surrounding cells (by releasing the same kynurenines). 
We recently reported that DEX potentiated cytokine-induced Ido1-FL expression by 
OHSCs [57]. Since i.p. LPS does not appreciably access the brain, central Ido1-FL induction by 
inflammatory stimuli is accepted to be mediated by cytokines [71], [75], [123], [220], especially 
via IFNγ and TNFα . Thus, DEX might be expected to elevate LPS-induced Ido1-FL in vivo. [142]
However, brain, astrocyte and microglial LPS-induced Ido1-FL are not increased by DEX (Figure 
13A). This discrepancy is easily explained. Ex vivo, the cytokine concentration is set by the 
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investigator and DEX potentiates Ido1-FL expression [57]. However, DEX blocked peripheral 
cytokine expression, resulting in less potential for synergistic induction of Ido1 in the periphery. 
In the brain, DEX did not attenuate LPS-induced TNFα expression so expression of Ido1-FL 
remains elevated. This has direct clinical implications. Depressed patients often present with 
mildly elevated cytokine levels [171] and/or elevated glucocorticoids [199], [200]. Activation of 
the Kynurenine Pathway may be enhanced by their combination. Thus, an underappreciated 
interaction between low-grade inflammation and elevated glucocorticoids may drive central DO-
dependent depression. 
LPS and DEX regulate Ido2 transcripts in a manner distinct from Ido1 
Four laboratories independently reported the existence of Ido2 [79], [80], [221], [222]. 
Like Ido1, Ido2 also mediates and controls Trp metabolism to Kyn [99]. Despite performing the 
same enzymatic role, Ido1 and Ido2 have non-redundant functions in rheumatoid arthritis [83], 
[101]. This difference may result from differential regulation and/or cell-specific expression 
profiles as reported for liver, kidney and epididymis [80]. Also, myeloid- and plasmacytoid-
dendritic cells both express Ido2, but Ido1 was detected only in myeloid-dendritic cells [99]. 
Thus, although sharing enzymatic function, Ido1 and Ido2 do not necessarily co-localize to the 
same cell types and thus can be differentially regulated with unique functional consequences. 
LPS slightly increased hippocampal [120], [158] and frontal cortex [223] Ido2-Tot 
expression, although neither LPS nor DEX affected brain Ido2-Tot in the current study (Figure 
14J). However with isoform-specific assays, we found that LPS increased Ido2-v1, Ido2-v3 and 
Ido2-v6 in hippocampus [126] and several Ido2 isoforms were elevated by IFNγ in OHSCs [57], 
[126]. Those data demonstrate isoform-specific Ido2 regulation suggesting cell-type-specific 
responses. Indeed, Ido2-v1 is not increased by LPS or DEX in whole brain, but LPS induced Ido2-
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v1 expression in astrocytes and microglia (Figure 14A). Astrocyte Ido2-v6 expression was 
increased by both LPS and DEX (Figure 14D). However, the major cell type that expresses Ido2-
v1 and Ido2-v6 in the brain is neither astrocytes nor microglia (Control Ct of glia >> brain). Since 
expression of these isoforms in brain is largely unaffected by LPS or DEX, another non-
responsive cell-type(s) must express these Ido2 isoforms. Thus, changes within specific cell 
populations are not necessarily reflected by analysis of their resident tissue. 
Of the 9 Ido2 isoforms, 8 were detected within the liver. Ido2-v1 and Ido2-v6 were 
increased by LPS whereas hepatic expression decreased for Ido2-FL, Ido2-v2, Ido2-v3, Ido2-v4, 
Ido2-v7 and Ido2-v8 (reflected by decreased Ido2-Tot). The decrease in hepatic Ido2-Tot 
expression by LPS (Figure 14J) is consistent with reduced hepatic Ido2 in malaria infected mice 
[80]. Stress also decreased hepatic expression of Ido2-FL, Ido2-v3 and Ido2-v4 [86], but DEX 
alone did not regulate hepatic Ido2 (Figure 14) suggesting that stress-induced down-regulation 
of hepatic Ido2 is not mediated by glucocorticoids, but by inflammation [86]. In the lung, Ido2-
v2 is uniquely stable while other Ido2 isoforms follow an expected inflammatory induction by 
LPS and anti-inflammatory reduction by DEX. Spleen does not follow the same pattern. Ido2 
isoforms are induced by LPS and either further induced or not changed by DEX. A mechanism 
explaining elevation of two hepatic Ido2 isoforms and decreases in 8 other isoforms and 
differential expression of isoforms in lung and spleen awaits further investigation. Likely, these 
changes reflect cell-type specific responses. Also, the expression profiles of Ido2 demonstrate 
unique patterns of regulation by LPS and DEX when compared to Ido1, consistent with previous 
reports and supporting non-redundant physiology. 
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DEX upregulates Tdo2-FL while inflammation regulates Tdo2-v1 and Tdo2-v2  
The first papers confirming DO isoform existence reported high Tdo2-v1 and Tdo2-v2 in 
mouse liver compared to brain [55]; results now extended to include Tdo2-FL (Figure 15A, [57], 
[86]). Within the liver, Tdo2 activity is glucocorticoid-dependent [63]–[65], [224], in line with 
DEX elevating Tdo2 expression (Figure 15). Tdo2-FL was also elevated in brain, astrocytes, liver, 
lung and spleen (but not microglia) by DEX; suggesting that Tdo2-FL is a glucocorticoid-sensitive 
Tdo2 isoform, albeit with cell-type specificity. 
Tdo2-v1/v2 expression by brain is unresponsive to LPS or DEX (Figure 15B-C). However, 
LPS (liver, spleen) and DEX (liver, lung) increase their expression in the periphery. This suggests 
that peripheral Tdo2-v1/v2 expression is sensitive to both pro-inflammatory mediators and 
glucocorticoids, but in a tissue-specific manner. Thus, inflammation- and glucocorticoid-
dependent signals drive peripheral Tdo2-v1/v2 expression, whereas glucocorticoid-receptor-
mediated signals drive peripheral and brain Tdo2-FL. 
Downstream Kynurenine Pathway enzyme regulation by LPS, DEX and LPS+DEX 
While the DOs are rate-limiting, downstream enzymes are expressed with cellular 
specificity and define which downstream Kyn's are produced [32], [54]. These Kyn's are 
categorized as neuroprotective (KynA), immunosuppressive (Kyn and KynA), neurotoxic (QuinA) 
and nicotinamide/NAD+ precursor (QuinA) [32], [54]. Some of the actions of the Kyn's are 
mediated extracellularly by transmembrane receptors [42], [46], requiring cellular release. 
Other actions are mediated by intracellular receptors [97], [225]. The latter case does not 
require release into the extracellular fluid and as such changes in the Kynurenine Pathway can 
affect the physiology of only that cell, making physiological relevance of tissue metabolite levels 
difficult to interpret. The best example, extracellular QuinA is neurotoxic via the NMDA-R , [226]
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but intracellular QuinA is used to generate NAD+ [227] and thus the Kynurenine Pathway is 
needed for neuroprotection . Thus, changes in downstream enzyme expression could shift [228]
the relative production of these Kyn's. 
Kat2 facilitates Kyn metabolism to KynA. Kat2 is preferentially expressed by astrocytes 
(Figure 16A) [137] and neurons [156]. Stress increases brain KynA [37], [119], [125]. However, 
these changes were not associated with changes in Kat2 expression (Figure 16A), [86], [119], 
[125]. Similarly, LPS increases central KynA without changes in Kat2 [53]. These findings 
demonstrate that KynA levels change independently of Kat2, confirming that KynA generation is 
dependent on Kat2 substrate availability (i.e. increased astrocyte DO-dependent Kyn 
production).  
Kmo, Kynu and Haao facilitate QuinA generation from Kyn. In brain, these enzymes are 
predominantly expressed by microglia (Figure 16B-D), [32], [54]. In the current study, LPS 
and/or DEX ~halved Kynu and Haao expression in microglia, liver, lung and spleen, albeit 
doubling Kmo in liver and lung (Figure 16B-D). These finding agree with other work showing 
only minor changes in these enzymes by inflammation [158] and stress [86], [119] compared to 
Ido1 and Ido2 induction (Figure 13 and Figure 14). These and other data suggest that changes in 
plasma or sera levels of Kyn's are dependent on changes in expression of the rate-limiting DOs 
[52], [210], [229]–[231]. Even so, enzymes downstream of the DOs are important therapeutic 
targets [50], [53]. Thus, examining defects-in or therapeutic manipulation-of downstream 
Kynurenine Pathway activity is an active area of preclinical research. 
Conclusions 
Here we show that Ido1, Ido2 and Tdo2 are uniquely regulated by LPS and DEX with 
elaborate cell-, tissue- and isoform-specificity. We identify DO isoforms uniquely adapted to 
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independently change in response to inflammation and glucocorticoids. Although only the first 
step towards defining the biological significance of their expression, our data begin to unravel 
the complex interactions between inflammation and stress regarding activation of Kynurenine 
Pathway enzymes under these often comorbid conditions. Importantly, the effects of 
inflammation and stress require different assays to identify treatment-specific changes in DO 
isoform expression. For instance, we show that both astrocytes and microglia respond to LPS by 
increasing Ido1-FL expression, but DEX increases Ido1-v1 expression by both cell-types. The 
expression of Ido1 was not attenuated by DEX in brain as was observed in peripheral tissues, 
demonstrating that the brain displays a differential response in the context of an inflammatory 
challenge coupled with elevated glucocorticoids. Taken together, our current findings provide 
novel evidence of a brain-specific interaction between inflammation and stress which may 
define a unique mechanism pivotal to the depression susceptibility of individuals affected by 
chronic inflammatory disease.   
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CHAPTER 4: Ido1 expressed by myeloid-derived cells contributes to brain 
Kynurenine Pathway activity and inflammation-induced anhedonia 3 
4.1 Abstract 
Depression is associated with central neuro-inflammation and symptoms of depression 
manifest following central or peripheral pro-inflammatory stimuli. In humans and rodents, 
respectively, symptoms of depression and depression-like behavior have been associated with 
the cytokine-inducible enzyme indoleamine 2,3-dioxygenase (Ido)1. While global Ido1 knockout 
mice are protected from anhedonia following an immune challenge with lipopolysaccharide 
(LPS), the cellular sources of Ido1 underpinning this effect remain unknown. To address this 
issue, we bred mice with lox-P gene inserts flanking Ido1 to mice expressing Cre-recombinase in 
myeloid-derived cells including brain microglia (M-Cre, Lyz2 promoter) or neurons (N-Cre, 
Camk2a promoter) generating cell-type specific Ido1 knockdown models. We hypothesized 
both myeloid- and neuron-derived Ido1 could contribute to anhedonia following a peripheral 
injection with LPS. Loss of myeloid Ido1 (Ido1fxM-Cre mice) attenuated the LPS-induced 
anhedonic response (assessed as sucrose preference), whereas loss of neuronal Ido1 (Ido1fxN-
Cre mice) had no effect on LPS-induced anhedonia. These behavioral responses paralleled a 
decreased kynurenine to tryptophan (Kyn/Trp) ratio in the brains of Ido1fxM-Cre mice but not 
in the brains of Ido1fxN-Cre mice. Plasma Kyn/Trp was not affected in either knockdown model. 
These results indicate that microglia-derived (and not neuron-derived) Ido1 contributes to the 
anhedonic response following a peripheral inflammatory challenge. LPS induced brain Ifnγ and  
3 Edited from original manuscript in prep with headings, figures, and tables renumbered:  
Dostal CR, et al. Ido1 expressed by myeloid-derived cells contributes to brain Kynurenine 
Pathway activity and inflammation-induced anhedonia. in prep 
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Tnfα mRNA expression to a similar degree in both Ido1xM-Cre and Ido1xN-Cre mice relative to 
their respective controls, indicating that the protective effect was not associated with 
diminished neuroinflammation. LPS-induced upregulation of Ido1-v1 (the main Ido1 transcript 
found in the mouse brain), but not Ido1-FL, was absent in both Ido1fxM-Cre and Ido1fxN-Cre 
mice. Collectively, these data suggest that Ido1 within neurons and microglia play distinctive 
roles in animal behavior. 
4.2 Introduction 
 Depression is the leading cause of global disability affecting over 350 million people 
worldwide [232], with an annual economic burden estimated at $70 billion and rising [233]. 
Primary depressions are rare as over 70% of cases present with one or more comorbidities 
[108]. Patients with conditions that chronically activate the immune system are especially 
vulnerable to depression, even when they have no prior history of mental disorders [29], [234]. 
The Monoamine Theory of Depression hypothesized that major depressive disorders results 
from reduced monoaminergic (e.g. dopaminergic, adrenergic, serotonergic) signaling; however, 
evidence-based pharmacotherapy fails to fully substantiate this claim [28], [40]. In fact, anti-
depressants have marginal efficacy and unfavorable side-effects [235]. More recently, evidence 
from human and animal studies supporting a link between inflammation, depression and 
Kynurenine Pathway metabolism has laid the groundwork for proposing the new Kynurenine 
Theory of Depression which holds that an imbalance in central levels of kynurenine (Kyn) 
metabolites mediate or precipitate symptoms of depression [32]. 
 The observation that depression symptomology is associated with elevated Kynurenine 
Pathway metabolite levels in patients receiving cytokine treatments for cancer  and hepatitis C 
[236], [237] has resulted in large-scale investigations into the immune system’s role in 
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depression [28], [29], [31], [34], [40], [73], [74], [76], [77], [159], [234], [236]–[241]. Kynurenine 
(Kyn) is generated from tryptophan (Trp) by three rate-limiting indoleamine/tryptophan 2,3-
dioxygenases (DOs: Ido1, Ido2 and Tdo2) [54]. These DOs and their various isoforms are 
regulated with incredible specificity by inflammation [57], [126], [190], [242] and stress [86].  
 Animal models have been used to show that systemic administration of Kyn to mice 
dosage-dependently elicits depressive-like behaviors [33]. While Kyn is transported across the 
blood-brain barrier[78], Kyn itself is not widely considered as neuro-modulatory. Kyn must be 
metabolized into its downstream neuro-active metabolites, the downstream kynurenines 
(Kyns) [54]. Importantly, the enzymatic machinery downstream of the DOs are cell-specific, 
resulting in specialized cellular generation of Kyns [54]. Specifically, microglia release quinolinic 
acid (QuinA) [124] while neurons produce more kynurenic acid (KynA) and picolinic acid (PicA) 
[243] (Figure 17). Several publications support the current dogma which holds that 
inflammation induces Ido1-dependent QuinA secretion by microglia. The neuro-toxic QuinA 
then mediates Ido1-dependent depression-like behaviors [67]. However, to our knowledge this 
is the first report to directly test this hypothesis using Cre-Lox technology to generate cell-type 




Figure 17. Increased Indoleamine 2,3-dioxygenase (IDO) 1 activity in microglia 
and neurons result in the production of distinct neuroactive metabolites. Ido1 
expressed in microglia is rate-limiting for the production of quinolinic acid, 
while Ido1 expressed in neurons is rate-limiting for the production of 
kynurenine acid. [32], [124], [243] 
4.3 Methods 
Animals 
Ido1 transgenic 'floxed' mice (Ido1f) were generated by inGenious Targeting Laboratory 
(Stony Brook, NY). Exons 3-5 were flanked by loxP sites enabling Cre-recombinase excision of 
the three exons. Comparison of the excision site to the commonly used Ido1 knockout mouse is 
shown in Figure 18. Cell-type specific knockdown mice were generated by breeding Ido1f mice 
to mice expressing Cre-recombinase in either myeloid-derived [244], [245] cells (M-Cre: stock # 
004781, B6.129P2-Lyz2tm1(cre)Ifo/J, Jackson Laboratories, Bar Harbor, MN) or in neurons [246], 
[247] (N-Cre: stock # 012362, B6;129S6-Tg(Camk2a-cre/ERT2)1Aibs/J, Bar Harbor, MN). All mice 
are on a C57BL/6J background and floxed mice were bred to homozygosity such that both Ido1 
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alleles could be excised by Cre-recombinase. Cre-mediated recombination is constitutive in M-
Cre mice, but recombination was induced in N-Cre strains with 1-week ad lib access to 
tamoxifen-supplemented chow (TD.130857, Harlan Laboratories, Madison, WI).  
 
Figure 18: Illustration of Ido1 excision sites. The Ido1-flox mouse used in this 
study has exons 3-5 flanked by loxP for Cre-mediated cell-specific excision. For 
comparison, the exons removed (4-6) from the commonly used Ido1 knockout 
mouse (Ido1-KO) are also illustrated. 
Male mice were housed on reversed 12 h light-dark cycle with ad lib access to chow and 
water. Mice were individually housed at least 2 weeks and handled for 5 consecutive days prior 
to experiments. Mice were 12 to 15 weeks of age at the time of study. Animal procedures were 
approved by the Institutional Animal Care and Use Committee and performed in accordance 
with the Guide for the Care and Use of Laboratory Animals (National Research Council). 
Genotyping and verifying Cre-lox mediated recombination.  
After mice were sacrificed and intracardially perfused with 4°C saline, brain and liver 
was harvested and processed for DNA. Mice genotype was verified by PCR using the following 
primers:  
 Cre forward:  AATGCTTCTGTCCGTTTGCCGGT 
 Cre reverse:  CCAGGCTAAGTGCCTTCTCTACA 
 
 Ido1 floxed forward:  GGGCTTCCAAGTGCTGTCTATG 
 Ido1 ∆ forward: GCTGACAACCTTAAAGCCATCTCATTC 
 Ido1 reverse:  CGAGAGTGTATTTTCTGGGTGC.  
Following electrophoresis through 7.5 % polyacrylamide gels and staining with ethidium 
bromide, the presence of Cre was confirmed in brain tissue by observation of a 518 bp band 
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using a LAS-4000 (Fujifilm Life Sciences, Stamford, CT). Ido1 flox status was also confirmed in 
brain tissue (WT allele 564 bp band, floxed allele 740 bp band), as well as Cre-mediated 
recombination (Δ allele 390 bp band) (Figure 19).  While the Δ band was constitutively present 
in brains of naïve Ido1fxM-Cre mice, the Δ band was only present in the brains of tamoxifen fed 
Ido1fxN-Cre animals (data not shown). This confirms the constitutive activity of the M-Cre 
recombinase and the conditional tamoxifen-induced activation of the N-Cre recombinase, 
respectively. Moreover, the Δ band was present in livers of Ido1fxM-Cre mice but not 
tamoxifen-fed Ido1fxN-Cre mice (data not shown), illustrating tissue-specificity for the neuronal 
Ido1 knockdown model but the ability of M-Cre to also excise the Ido1 exons in myeloid-derived 
cells of a peripheral tissue.  
 
Figure 19: Cre-induced gene recombination in brain. PCR on DNA extracted 
from saline perfused brain tissue from wild-type (WT) mice and (A) M-Cre 
strains or (B) N-Cre strains verified the Ido1 WT allele (564 bp) Ido1-flox allele 
(740 bp) and recombinant ∆ allele (390 bp) as indicated bands on the left 
panels. The presence of the Cre allele (518 bp) was also verified as indicated by 
bands on the right panels. 
Sucrose Preference, Body Weight and Food Intake. 
Mice were trained for 4-5 d with access to a bottle containing water and an identical 
bottle containing 1% sucrose. Each morning, both bottles were weighted and change in weight 
was calculated for both the water and sucrose bottles. The 24 h sucrose preference was 
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calculated as a percentage: [(gram change in sucrose)/(gram change in sucrose + gram change 
in water)] x 100. Training was complete when all mice had established a greater than 85% 
preference for the sucrose solution. Mice were then injected immediately prior to onset of the 
dark cycle with either saline (controls: Ctrl) or saline to deliver 0.83 mg/kg body weight of 
lipopolysaccharide (LPS serotype O127:B8, Sigma). Sucrose preference, body weights and chow 
consumption were recorder for the next 4 days after treatment. 
Table 3: Effect of LPS on body weight and food intake. 
 M-Cre  Ido1fxM-Cre  
 Ctrl  LPS  Ctrl  LPS 
∆ Body Wt. (g) 0.4 ± 0.1  -1.1 ± 0.1 *  0.8 ± 0.2  -1.1 ± 0.2 * 
Food Intake (g) 0.9 ± 0.1  0.1 ± 0.1 *  1.0 ± 0.2  0.0 ± 0.2 * 
                
 N-Cre  Ido1fxN-Cre 
 Ctrl  LPS  Ctrl  LPS 
∆ Body Wt. (g) 0.0 ± 0.1  -1.6 ± 0.1 *  0.0 ± 0.2  -1.6 ± 0.2 * 
Food Intake (g) 1.5 ± 0.1  0.2 ± 0.1 *  1.6 ± 0.1  0.2 ± 0.1 * 
* p < 0.05 for the effect of LPS 
Quantitative polymerase chain reaction (qPCR) 
Ctrl and LPS-treated mice were euthanized using CO2 5 h after treatment. Following 
intracardial perfusion with ice-cold saline, brains were removed, homogenized, suspended in 
TRIzol and stored at -80 °C until processed for gene expression. Materials and methods for RNA 
extraction, reverse-transcription and qPCR were recently described [86]. Expression of each test 
gene is normalized to Gapdh using the 2-ΔΔCt method [131]. Gene expression for the Ctrl groups 
is set to 1.0 and other groups are expressed as fold of Ctrl. Ido1 gene structure, mRNA 
transcripts and probe-based assays (IDT, Coralville, Iowa) quantifying each Ido1 transcript were 
recently described [86]. Because of low expression, some transcripts are 'not detectable' in all 
samples (i.e. Ct values 'undetermined') preventing calculation of relative gene expression levels. 
For analysis a Ct value of 40.0 is assigned when this occurs. Treatment efficacy during the 5 h 
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post-treatment period was confirmed by a reduction of body weight and food intake by LPS 
(Table 3). These changes were unaffected by Ido1 status. 
High performance liquid chromatography (HPLC) for Kyn. 
A separate cohort of mice were treated with saline (Ctrl) or LPS and sacrificed 24 h after 
treatment. Blood was collected from the inferior vena cava immediately prior to intracardiac 
perfusion with ice-cold saline. After perfusion, brains were harvested, snap frozen in liquid N2 
and then stored at -80 °C. To measure Trp and Kyn concentrations, the brain and plasma 
samples were processed for HPLC and quantified using electrochemical detection as recently 
described [86], [95], [132], [242].  
Statistics 
Data are presented as means ± SEM representing 4-8 mice per group. Two-way 
repeated measures ANOVA was used when determining significant treatment effects at 
different time points. Two-way ANOVA was used when determining significant effects of LPS 
and genotype at a single time point. Significance was set at p ≤ 0.05. Significant main effects of 
LPS or genotype are annotated with * or φ, respectively. Data annotated with δ represent 
significant effects by post hoc analysis using the Holm-Šídák method when a significant LPS x 
genotype interaction occurred. Plotting and statistical analysis were completed using SigmaPlot 
13.0. 
4.4 Results 
Mice deficient for Ido1 in either myeloid-derived cells (Ido1fxM-Cre) or neurons 
(Ido1fxN-Cre) were generated to determine if Ido1 expressed in these cell-types contribute to 
anhedonic-like behavior induced by inflammation [68].  
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Myeloid-derived Ido1 contributes to symptoms of inflammation-induced anhedonia 
and brain Kynurenine Pathway activity and Ido1 expression. 
Peripheral administration of LPS results in an acute sickness response readily measured 
as a loss of body weight [29], [33]. Expectedly, 24 h after treatment the LPS-treated mice 
experienced reduction in body weight relative to saline treated mice (Figure 20A). This effect 
occurred independent of genotype suggesting that the Ido1 in myeloid-derived cells does not 
contribute to the LPS-induced sickness response. Likewise, 5 h after LPS treatment, brain Ifnγ 
and Tnfα gene expression increased similarly in both M-Cre and Ido1
fxM-Cre mice relative to 
their saline treated Ctrls (Figure 20C). However, LPS-treated mice demonstrated reduced 
sucrose preference in the 24 h following treatment with a significant treatment x time 
interaction such that LPS-induced anhedonia was attenuated in Ido1
fxM-Cre mice relative to M-
Cre mice (Figure 20B). Inflammation-induced anhedonia was resolved in both M-Cre and 
Ido1
fxM-Cre mice with no treatment-effects of LPS treatment by 48 h after treatment.  
The plasma Kyn/Trp ratio was increased in LPS treated mice independently of genotype, 
demonstrating that this well-documented effect occurring 24 h after treatment is independent 
of Ido1 derived from cells of myeloid lineage (e.g. monocytes, macrophages, neutrophils, etc.). 
Importantly, Ido1
fxM-Cre mice have lower brain Kyn/Trp relative to M-Cre mice independently 
of LPS-treatment suggesting that myeloid-derived cells contribute to Kynurenine Pathway 
activity in the brain (Figure 20D). Moreover, 5 h after LPS treatment, brain Ido1-FL expression 
increased 200-fold in M-Cre mice but only 110-fold in Ido1
fxM-Cre mice, albeit this occurred 
independently of genotype (Figure 20E). Thus, LPS-induced Ido1-FL expression was numerically 
but non-significantly lower in brains of LPS-treated Ido1
fxM-Cre mice relative to LPS-treated M-
Cre mice. Brain Ido1-v1 expression was induced by LPS 5 h after treatment in M-Cre control 
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mice but was not LPS-inducible in Ido1
fxM-Cre mice (Figure 20E). Brain Ido1-v2 expression was 
not significantly induced by LPS 5 h after treatment; however, brain Ido1-v2 expression was ~3-
fold greater in Ido1
fxM-Cre versus M-Cre mice suggesting some compensatory upregulation of 
Ido1-v2 expression in brain by an unidentified and non-myeloid-derived cell-type(s). 
These data demonstrate that myeloid-derived Ido1 specifically contributes to 
inflammation-induced anhedonic-like behavior (Figure 20B), as well as brain (but not plasma) 
Kynurenine Pathway activity (Figure 20D). Importantly, unlike global Ido1KO mice [68], these 
animals are not completely protected from the reduced sucrose preference initiated by i.p. LPS 
suggesting that Ido1 activity in other cells within the brain also contribute to Ido1-depenent 




Figure 20. Myeloid-derived Ido1 contributes to symptoms of inflammation-induced anhedonia 
and brain Kynurenine Pathway activity and Ido1 expression. Mice deficient in myeloid-derived 
Ido1 (Ido1fxM-Cre) and their genetic controls (M-Cre) were treated i.p. with saline (Ctrl) or saline 
containing LPS and then monitored for changes in (A) body weight and (B) sucrose preference to 
determine differences in LPS-induced anhedonia. 5 h after Ctrl or LPS treatments, (C) brain mRNA 
expression of Ifnγ and Tnfα is measured. 24 h after treatments, the (D) plasma and brain Kyn/Trp 
ratio is assessed representing Kynurenine Pathway activity. 5 h after treatments, (E) brain mRNA 
expression of Ido1-FL, Ido1-v1, and Ido1-v2 is measured. † represents p < 0.05 by 2-way repeated 
measures ANOVA when a significant treatment x time interaction occurs. * represents p < 0.05 
main effect of LPS, φ represents p < 0.05 main effect of mouse genotype, δ represents p < 0.05 
when a significant LPS x genotype interaction occurs by 2-way ANOVA. 
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Neuron-derived Ido1 makes transcript-specific contributions to brain Ido1 gene 
expression. 
LPS treatment resulted in reductions in both body weight (Figure 21A) and sucrose 
preference (Figure 21B) relative to saline treatments (Ctrl); these effects were independent of 
neuronal Ido1 knockdown status. Thus, unlike the mice deficient in myeloid-derived Ido1, the 
inflammation-induced sickness response and anhedonia-like behavior are both similar in 
Ido1fxN-Cre mice and N-Cre mice. Likewise, 5 h after treatment the LPS-induced increases in 
brain Ifnγ and Tnfα gene expression were completely independent of neuronal-Ido1 knockdown 
status (Figure 21C). Thus, neuronal-Ido1 knockdown does not result in differences in neuro-
inflammation initiated by i.p. LPS treatments. Relative to Ctrl, LPS also increased plasma and 
brain Kyn/Trp to a similar extent in N-Cre and Ido1fxN-Cre mice when assessed 24 h after 
treatment (Figure 21D). This indicates that neuronal-Ido1 does not contribute to LPS-induced 
increases in either brain or plasma Kyn/Trp. Thus, conditional knockdown of neuronal-Ido1 
does not protect mice from LPS-induced anhedonia-like behavior, nor does neuronal-Ido1 
knockdown perturb the neuro-inflammatory response initiated by LPS or plasma and brain 
Kyn/Trp levels in naïve or LPS treated mice.  
Ido1 expression was assessed in whole-brain 5 h following i.p. Ctrl or LPS injections. 
Ido1-FL expression was increased 320-fold in both N-Cre and Ido1fxN-Cre by LPS independently 
of genotype (Figure 21E). Ido1-v1 expression was upregulated by LPS in N-Cre control mice; 
however, it was not LPS-inducible in Ido1fxN-Cre mice. Ido1-v2 gene expression was 72-fold 
greater in Ido1fxN-Cre mice relative to N-Cre control genotypes; however, Ido1-v2 was not LPS 
inducible in either N-Cre or Ido1fxN-Cre mice. This demonstrates major compensatory 
upregulation of Ido1-v2 expression in mice deficient in neuron-derived Ido1.  
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Together, these data suggest that neuron-derived Ido1 plays no role in inflammation-
induced anhedonic-like behavior. However, Ido1
fxN-Cre mice also exhibits remarkable 
compensatory upregulation of Ido1-v2 when compared to N-Cre controls which likely 
compensates for neuronal-Ido1 knockdown within in a non-neuronal and undetermined cell-
type(s). Because of this striking upregulation of Ido1-v2, the neuronal contribution of Ido1 to 




Figure 21: Neuron-derived Ido1 makes transcript-specific contributions to brain Ido1 gene 
expression. Mice deficient in neuron-derived Ido1 (Ido1fxN-Cre) and their genetic controls (N-
Cre) were treated i.p. with saline (Ctrl) or saline containing LPS and then monitored for changes 
in (A) body weight and (B) sucrose preference to determine differences in LPS-induced 
anhedonia. 5 h after Ctrl or LPS treatments, (C) brain mRNA expression of Ifnγ and Tnfα is 
measured. 24 h after treatments, the (D) plasma and brain Kyn/Trp ratio is assessed representing 
Kynurenine Pathway activity. 5 h after treatments, (E) brain mRNA expression of Ido1-FL, Ido1-v1, 
and Ido1-v2 is measured. * represents p < 0.05 main effect of LPS, φ represents p < 0.05 main 
effect of mouse genotype, and δ represents p < 0.05 when a significant LPS x genotype 




Inflammation-induced anhedonia initiated by LPS administered into the periphery or 
brain is Ido1-dependent [68], [212]; however, the Ido1 expressing cell-type(s) mediating this 
response is undefined. Since microglia [76], [142], [189], [242] and neurons [124], [243], [248] 
respond to inflammation with Ido1 upregulation, we generated mice deficient in either 
myeloid- or neuron-derived Ido1 to distinguish contributions of these cell-types to 
inflammation-induced anhedonia.  
Myeloid-derived Ido1 contributes to symptoms of inflammation-induced anhedonia 
and brain Kynurenine Pathway activity and Ido1 expression. 
Mice deficient in myeloid-derived Ido1 are protected from the full spectrum of the 
anhedonic response induced by LPS (Figure 20B). The M-Cre system is effective at excising 
floxed alleles of both central (e.g. microglia) and peripheral (e.g. monocytes) myeloid-derived 
cells [244], [245]; however, Ido1fxM-Cre mice have reduced Kyn/Trp in saline perfused brain, 
not plasma (Figure 20D), demonstrating a functional effect of myeloid-derived Ido1 knockdown 
on brain Ido1 activity. While the increases in central and peripheral Kynurenine Pathway activity 
following LPS injection are well documented [54], [242], the cellular origins driving increased 
Kyn/Trp have been undefined. Our data indicates that LPS increases peripheral Kyn/Trp 
independently of Ido1 induction by myeloid-derived cells (e.g. Macrophages, monocytes, 
neutrophils, etc). Clearly, central myeloid-derived cells influence brain Kyn/Trp, but these cells 
may include perivascular, meningeal, and choroid plexus macrophages in addition to 
parenchymal microglia [249]. Likewise, LPS treatment reportedly increases trafficking of 
myeloid-derived cells from the blood into the brain where their phenotype may be altered 
[250], [251]. Nonetheless, precisely determining to what extent Ido1 from each of these various 
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myeloid-derived cells contributes to brain Kynurenine Pathway activity was out of the scope of 
the current study.  
LPS treatment induces Ido1-FL in microglia [189], [190], [242], and inflammation-
induced Ido1-FL is cytokine-dependent [75], [142]. Importantly, we verified that Ido1fxM-Cre 
and M-Cre mice have similar brain cytokine responses to LPS treatment (Figure 20C) which is 
consistent with reports of LPS inducing pro-inflammatory cytokines to a similar extent in brains 
of wild-type and global Ido1KO mice [67], [212]. Brain Ido1-FL expression in LPS treated Ido1fxM-
Cre mice was nearly ½ of Ido1-FL expression in LPS treated M-Cre mice (Figure 20E). The 
reduction of Ido1-FL expression in the brain of Ido1fxM-Cre mice was non-significant as 
microglia only represent a small fraction of brain cells; most other cell-types in the brain are 
expected to respond to LPS treatment with Ido1-FL potently induced [54], making the effects of 
myeloid-targeted Ido1 knockdown difficult assess in brain.  
Total knockout strategies have demonstrated that Ido1 is necessary for LPS-induced 
anhedonia [68]; however, until this report the cellular-specificity of this response was 
undefined. These data strongly suggest that myeloid-derived cells within the brain (i.e. 
microglia, brain-associated macrophages) contribute to the inflammation-induced anhedonic 
response of mice. 
Neuron-derived Ido1 makes transcript-specific contributions to brain Ido1 gene 
expression. 
Mice deficient in neuron-derived Ido1 (Ido1fxN-Cre) respond with similar LPS-induced 
anhedonic-like behavior as their LPS treated control (N-Cre) mice (Figure 21B). The neurons 
expressing Cre recombinase in this model are glutamatergic [252]. The Camk2a promoter 
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targets Cre recombinase expression mostly to excitatory neurons in forebrain areas, including 
the hippocampus and striatum [247]. While Ido1 derived from these excitatory neurons may 
not be driving the inflammation-induced anhedonia of mice, these excitatory neurons project 
to other brain regions of the mesolimbic dopamine reward system such as the nucleus 
accumbens and the ventral tegmental area [253]. Neuronal production of kynurenine acid 
(KynA) [156], [243] in these brain regions may regulate dopamine [254], [255] or GABA [256] 
synaptic transmission. Nevertheless, determining the extent to which Ido1 derived from other 
neuronal cell-types including GABAergic neurons of the nucleus accumbens or dopaminergic 
neurons of the ventral tegmental area was out of the scope of the current work. 
As N-Cre and Ido1fxN-Cre responded to LPS with similarly elevated plasma and brain 
Kyn/Trp (Figure 21D), the LPS-induced expression of Ido1-FL in brains of these mice was also 
similar (Figure 21E). Remarkably, Ido1-v2 expression is ~80-fold greater in brains of Ido1fxN-Cre 
mice relative to N-Cre controls. The Ido1-v2 transcript is poorly expressed in the naïve mouse 
brain where its expression is still undetectable after LPS treatment, albeit LPS-sensitive in lung 
tissue [242]. Thus, the compensatory upregulation of Ido1-v2 in whole brain of Ido1fxN-Cre 
mice is a surprising result; however, the brain-region(s) or cell-type(s) mediating this effect 
remains undefined.  
While global Ido1KO mice are protected from LPS-induced anhedonia [68], the effects of 
N-Cre mediated neuronal-Ido1 knockdown on animal behavior were difficult to ascertain 





The normal hedonic activity (sucrose preference) of naïve mice was unaffected by either 
myeloid- or neuronal-knockdown of Ido1. However, mice deficient in myeloid-derived Ido1 
(Ido1fxM-Cre) had an attenuated anhedonic response to i.p LPS. Similar proinflammatory 
responses were induced by LPS in both Ido1fxM-Cre and Ido1fxN-Cre mice relative to their 
genetic controls. Even so, the Kyn/Trp ratio was only lower in brains, not plasma, of Ido1fxM-
Cre mice, suggesting Ido1 from microglia (and not neurons) contribute to inflammation-induced 
anhedonia. The mRNA expression of three Ido1 isoforms was quantified in whole brain. LPS-
induced Ido1-v1 upregulation was absent in both Ido1fxM-Cre and Ido1fxN-Cre mice, but not 
their respective controls. However, there was a remarkable upregulation of Ido1-v2 in brains of 
Ido1fxN-Cre mice relative to N-Cre control brains, suggesting glial compensatory upregulation in 
response to neuronal Ido1 knockdown. Unlike N-Cre strains, the Ido1-FL induction by LPS in 
brains of M-Cre control mice was roughly double that of Ido1fxM-Cre mice, signifying that Ido1-
FL is not full induced due to microglia Ido1 knockdown. Together, these data demonstrate that 
Ido1 within neurons and microglia play distinct role in animal behavior, and that microglia-
derived Ido1 likely contributes to inflammation-induced depression-like behavior.  
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CHAPTER 5: Conclusion 
5.1 Conclusion 
These data recognize a unique role for astrocytes in the DO response to acute stress 
without any significant effects of acute stress on the DO regulation in microglia. Moreover, 
we describe unique regulation patterns for microglia and (a more underappreciated role 
for) astrocytes and in the DO response to peripheral inflammation and exogenous 
glucocorticoid. Importantly, glucocorticoids fail to suppress inflammation-induced DOs 
with the brain and glia whereas they are effective on DOs in the periphery in a DO-specific 
and tissue-specific manner. Finally, possibly owing to a robust compensatory upregulation 
of Ido1-v2 following neuronal knockdown of Ido1, there were no discerned effects 
neuronal Ido1 knockdown on animal behavior. Both myeloid- and neuronal-Ido1 
knockdown mice did not upregulated Ido1-v1 in response to LPS; however, their respective 
genetic control mice had normal Ido1-v1 responses. Lastly, these data strongly suggest 
microglia contribute to inflammation-induced anhedonia-like behavior in the Ido1fxM-Cre 
mice. Together, these data highlight DO regulation by stress and inflammation in a glia- and 
tissue-specific manner, and cell-specific contributions of Ido1 to inflammation-induced 
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